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Approximately 30% of myocarditis patients progress to develop dilated cardiomyopathy, 
which is a major cause of sudden death in children and young adults. Ly6Chi inflammatory 
monocytes are thought to play a detrimental role in a mouse model of experimental 
autoimmune myocarditis (EAM). Their recruitment in large numbers to the heart has been 
linked to cardiac fibrosis and ventricular dysfunction. However, the mechanism underlying 
the pathogenic role of Ly6Chi monocytes has been overlooked, and the protective role of 
Ly6Clo monocytes was largely presumed based on extrapolation from other disease 
models. We therefore studied the fates and functions of these two types of monocytes to 
better understand their roles in the injured myocardium. We demonstrated in vitro that 
cardiac fibroblasts mediate monocyte-to-macrophage differentiation through direct 
contact with Ly6Chi and Ly6Clo monocytes. IL-17A is significantly elevated during acute 
myocarditis. It signals through cardiac fibroblasts to abolish Ly6Clo monocyte-to-
macrophage differentiation as well as to hamper phagocytic function in Ly6Chi monocyte-
derived macrophages. Phagocytosis of apoptotic/necrotic myocardial cells by 
macrophages plays a crucial role in minimizing myocardial damage and subsequent 
dysfunction. Strikingly, cardiac IL-17A in heart failure patients is inversely correlated with 
phagocytic receptor expression in the myeloid compartment. This highlights the clinical 
relevance of our finding and can lead to the development of diagnostic biomarkers or 
novel treatment approaches. IL-17A signaling wanes during inflammation resolution, 
allowing Ly6Clo monocyte-to-macrophage differentiation to resume. These macrophages 
display antigen presentation properties which coincide with cardiac protection in IL-17Ra–
/– mice in vivo. In conclusion, we described how the inflammatory environment modulates 
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the phenotype and functions of infiltrating monocytes with potential implications for other 
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A. Myocarditis definition, diagnosis and etiology 
Myocarditis is responsible for a significant number of chronic and acute heart failure cases 
involving children and young adults [1]. Although the majority of affected patients recover, 
myocarditis contributes to the global cardiovascular disease burden mainly through the 
development of dilated cardiomyopathy and ultimately to sudden heart failure [2]. It is 
often challenging to diagnose myocarditis due to the its broad range of clinical 
presentations and heterogenous disease manifestation [3-5]. Currently the diagnostic 
gold standard of myocarditis is endomyocardial biopsy (EMB) and is based on histological, 
immunological and immunohistochemical criteria [5]. Established in 1986, the Dallas 
criteria provides a histopathological definition for myocarditis that require the presence of 
inflammatory infiltrates in the myocardium accompanied by cardiomyocyte deterioration 
and necrosis not characteristic of an ischemic event [6, 7]. In 2013 the European Society 
of Cardiology Working Group on Myocardial and Pericardial Diseases published a 
statement emphasizing the importance of histological and immunohistochemical 
characterization to provide evidence for myocardial inflammation. The 
immunohistochemical criteria describing abnormal cardiac immune cell infiltrates was 
stated as “≥ 14 leucocytes/mm2 including up to 4 monocytes/mm2 with the presence of 
CD3 positive T-lymphocytes ≥ 7 cells/mm2” [8-10]. Therefore, EMB made it possible to 
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help distinguish unique subtypes of myocarditis with variable prognoses. It also allows for 
identification of the presence of viral genomes using molecular techniques such as 
reverse transcriptase-PCR with significant prognostic and therapeutic consequences [8, 
9, 11-16]. However, the limitations for EMB are its low sensitivity, high sampling error and 
potential for complications. The fact that it is an invasive procedure makes it less desirable 
for routine use and follow up [17]. Moreover, clinical presentations for myocarditis range 
widely from moderate chest pain with transient palpitations detectable by ECG to sudden 
cardiac death [3, 18-20]. As a result, other diagnostic methods such as cardiovascular 
magnetic resonance imaging (CMR) are increasingly being utilized in the initial diagnostic 
workup of suspected myocarditis patients (Table 1) [15, 21-23].  
 





Specificity and sensitivity for myocarditis 
Electrocardiogram Can be considered as part of the initial testing. However, myocarditis patients can show 
normal or nonspecific abnormalities or patterns similar to that of acute isolated pericarditis or 





















F-18 fluorodeoxyglucose (FDG) 




Elevated serum cardiac troponin levels are tested as an indicator for myocardial necrosis; 
elevated serum B-type natriuretic peptide (BNP) and N-terminal pro b-type natriuretic peptide 
(NT-proBNP) levels reflect diminished cardiac capacity. However, findings can be non-
specific. 
 
Of limited sensitivity, but used to view cardiac enlargement in the absence of pulmonary 
congestion. 
 
Optional test for evaluation of coronary status. 
 
Key method used to detect abnormal ventricular function even at the subclinical stage. Can 
detect abnormal ejection fraction and changes in ventricular geometry. Doppler 
echocardiography can be useful to assess blood flow, avoiding invasive measurements such 
as cardiac catheterization. This method has replaced Radionuclide ventriculography. 
 
CMR can be used as a powerful predictor of adverse cardiovascular outcomes. Specifically, it 
can distinguish myocarditis from ischemic cardiomyopathy, and allows the visualization of 
myocyte necrosis, fibrosis, changes in ventricular size and geometry. A combined imaging 
method termed “Lake Louise criteria†”. This method has largely replaced Gallium scanning, 
which detects severe myocardial infiltration. 
 
Relatively new imaging technology. Limited reports have shown high sensitivity and specificity 





This table is based on [24-39]. †Lake Louise criteria (proposed diagnostic CMR criteria) for myocarditis diagnosis means that in 
clinically suspected myocarditis cases at least two of the three following criteria need to be satisfied: 1) Myocardial signal intensity 
increases in T2-weighted images regionally or globally; 2) Myocardial early gadolinium enhancement ratio is increased globally 
between myocardium and skeletal muscle in T1-weighted images; 3) At least one non-ischemic focal lesion in inverse-recovery late 
gadolinium-enhancement T1-weighted images [40].  
 
 
Unfortunately, no single test can reliably confirm the diagnosis of many cases, which 
makes myocarditis diagnosis a challenging task and ultimately contributes to the 
underestimation of global myocarditis prevalence [3-5].  
Myocarditis can be caused by both infectious and non-infectious agents (Table 2). 
However, evidence suggests that viral infections such as coxsackie B3, parvovirus B19 
and adenoviruses are the most common causes of myocarditis in developed nations [3-
5, 7, 12, 14, 41-45]. Regardless of myocarditis etiology, clinical presentation of the acute 








> 60 known genes including most prevalent TTN, LMNA, MYH7, and the rarest TTNT2, Duchenne 
muscular dystrophy, Barth syndrome. 
 
Microorganisms   
BACTERIA Staphylococcus, Clostridium, Diphtheria, Chlamydia psittaci, Streptococcus, Pneumococcus, 
Meningococcus, Gonococcus, Salmonella, Corynebacterium diphtheriae, Haemophilus influenzae, 
Mycobacterium tuberculosis, Mycoplasma pneumoniae, Brucella Spirochaetal, Borrelia, Leptospira, 
Coxiella burnetiid, Rickettsia rickettsia, Syphilis 
 
RNA VIRUSES Coxsackie, Echoviruses, Poliomyelitis, Influenza, Respiratory syncytial virus, Mumps, Measles virus, 
Rubella virus, Hepatitis C virus, Dengue virus, Yellow fever virus, HIV-1, Chikungunya virus, Junin virus, 
Lassa fever virus, Rabies virus  
 
DNA VIRUSES Adenoviruses, Parvovirus B19, Cytomegalovirus, Epstein-Barr virus, Varicella-zoster virus, Herpes 
simplex virus, Variola virus, Vaccinia virus 
 
FUNGI Aspergillus, Actinomyces, Blastomyces, Candida, Coccidioides, Cryptococcus, Histoplasma, 
Mucormycoses, Nocardia, Sporothrix 
 
PROTOZOANS Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Toxoplasma 
gondii, Taenia solium, Entamoeba histolytica, Leishmania, Strongyloides, Ancylostoma duodenale, 
Necator americanus,  
  
HELMINTHS Echinococcus granulosus, Trichinella spiralis 
 
Toxins  
DRUGS Phenothiazines, Amphetamines, Anthracyclines, Cyclophosphamide, Cocaine, Cyclophosphamide, 5-
Fluorouracil, Lithium, Catecholamines, Hemetine, Interleukin, Trastuzumab, Clozapine, Tricyclic 
antidepressants, Dobutamine, Epinephrine, Dopamine, Norepinephrine, Phenylpropanolamine, Ferrous 
sulfate, Immune checkpoint inhibitors, Cholorquine, Zidovudine 
 
VENOMS Insect stings, Snake bites 
 
ENDOCRINES Hypo- or hyper-thyroidism, Diabetes mellitus, Cushing’s syndrome, Phaeochromocytoma, Growth 
hormones imbalance, Preganacy 
 
OTHERS Alcohol, Carbon monoxide, Phosphorus, Arsenic, Sodium azide, Heavy metal  
 
Hypersensitivity  
DRUGS Penicillin, Cefaclor, Colchicine, Furosemide, Isoniazid, Lidocaine, Tetracycline, Sulfonamides, 
Phenytoin, Phenylbutazone, Methyldopa, Thiazide diuretics, Amitriptyline, Tetanus toxoid 
 
Physical assault  
PROCEDURES Radiation, Electric shock, Heart transplantation rejection 
 
Systemic  
AUTOIMMUNE  Celiac disease, Hypereosinophilia, Systemic lupus erythematosus, Rheumatoid arthritis, Churg-Strauss 
syndrome, Kawasaki’s disease, Inflammatory bowel disease, Scleroderma, Polymyositis, Myasthenia 
gravis, Insulin-dependent diabetes mellitus, Thyrotoxicosis, Sarcoidosis, Wegener’s granulomatosis, 
Rheumatic heart disease, Dermatomyositis  
 




B. Selected forms of myocarditis 
 
EMB also permits immunopathological examination of the infiltrating leukocyte profile in 
the myocardium, which helps to further classify myocarditis into several forms. 
1. Lymphocytic myocarditis is the most common form of myocarditis, primarily defined 
by diffuse focal aggregates of cardiac T lymphocyte infiltrates, typically as a result of a 
viral respiratory tract infection. The severity of myocardial fibrosis is used to define the 
progression of lymphocytic myocarditis from acute to chronic phase [18]. Clinical 
presentation of lymphocytic myocarditis can vary widely from flu-like symptoms to 
fulminant left ventricular failure. Since a significant number of patients can also be 
asymptomatic, disease prevalence in the general population can be underestimated [52, 
56]. Approximately 50% of the patients were reported to survive without cardiac 
transplantation at five years from symptom onset [57]. Immunosuppressive drugs can 
significantly alleviate the worsening of ejection fraction in affected individuals if circulating 
autoantibodies against cardiac antigens are detected, whereas immunosuppressive 
treatments are ineffective in patients with detectable viral genomes in the heart [58, 59]. 
A murine CVB3-induced myocarditis model was developed to draw a parallel between 
human lymphocytic myocarditis (see experiment vial myocarditis model below) [60, 61].  
2. Eosinophilic myocarditis is a relatively rare form of myocarditis characterized by 
eosinophilic infiltrates in the myocardium and is often associated with peripheral 
eosinophilia [62]. Although the underlying etiology for eosinophilic myocarditis remains 
largely unknown, case reports have shown correlation of eosinophilic myocarditis patients 
with drug hypersensitivity and parasitic infections, and most commonly with the idiopathic 
hypereosinophilic syndrome [63-65]. Necrotizing eosinophilic myocarditis is the most 
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severe form, frequently presenting with acute onset, rapid progression and severe 
necrosis [56]. Immunosuppressive treatment doesn’t significantly improve long term 
prognosis, and disease outcomes are dire for the majority of patients [18, 56, 66]. A 
murine model has been developed to better understand the pathogenesis of eosinophilic 
myocarditis in humans [67]. 
3. Giant cell myocarditis is the rarest but most fulminant form of myocarditis with poor 
prognosis. It is characterized by the presence of multinucleated giant cells among 
numerous other cardiac infiltrates [56]. Histologically the predominant infiltrates consist 
of CD68+ macrophage lineage with the presence of T lymphocyte and frequently with 
eosinophils [68]. In contrast to the heterogeneous clinical features of lymphocytic 
myocarditis, giant cell myocarditis manifestation typically results in fulminant left 
ventricular systolic dysfunction and heart failure, with some patients developing 
ventricular arrhythmias and heart block [69]. The rapidly progressive nature of giant cell 
myocarditis results in poor survival with only about 11% of patients surviving over 4 years 
without a need of cardiac transplantation. Treatment with the appropriate 
immunosuppressive combination therapies can improve prognosis and increase survival 
rates, yet options are highly limited [69, 70]. Giant cell myocarditis is thought to be 
autoimmune in nature as 17 – 19% of patients typically suffer from other non-cardiac 
related autoimmune diseases [68, 69, 71]. A murine model termed experimental 
autoimmune myocarditis (EAM) closely resembles the phenotype of this disease [56]. 
4. Sarcoidosis, or idiopathic granulomatous myocarditis, is a heterogeneous disease of 
unknown etiology characterized by non-caseating granulomas in various organs, 
including the heart. The clinical presentation of sarcoidosis ranges from nonspecific 
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symptoms to sudden death caused by atrioventricular block and congestive heart failure 
despite having a relatively indolent clinical course [72, 73]. Sarcoidosis is associated with 
even higher rates of ventricular arrhythmias and heart block when compared to giant cell 
myocarditis [74]. Heart transplantation is often the treatment of last resort for end stage 
disease management. However, recurrence of sarcoidosis cannot be prevented with this 
approach [75].  
Regardless of etiology, acute myocarditis in susceptible populations can progress to 
subacute and chronic phase, and ultimately proceed to dilated cardiomyopathy (DCM). 
Myocarditis is responsible for approximately 9 – 16% of newly diagnosed DCM cases [76-
78]. DCM is the most common cardiomyopathy worldwide, and the major cause of heart 
failure in patients under the age of 40 [79]. According to the WHO/ISFC criteria, patients 
with DCM develop dilatation and systolic dysfunction (abnormality of contraction) of the 
left or both ventricles in the absence of abnormal loading conditions or coronary artery 
disease. DCM can be further categorized into several subtypes including idiopathic, 
familial/genetic, pathogen, autoimmune and environmental toxin [3, 5, 18, 42]. Although 
DCM is associated with fulminant congestive heart failure, patients may or may not 
experience overt heart failure. Both etiology and diagnosis of DCM largely overlaps with 
that of myocarditis (Table 1 and Table 2). Unfortunately, a clear mechanism of 
progression from myocarditis to dilated cardiomyopathy has not been elucidated.   
C. Experimental autoimmune myocarditis - murine model 
 
To improve current treatment regimens and to understand the mechanism of how 
myocarditis progress to heart failure, it was important to create a mouse model of 
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autoimmune myocarditis. The two main murine models of myocarditis are coxsackievirus 
B3 (CVB3) myocarditis and experimental autoimmune myocarditis (EAM). 
In humans, CVB is one of the most frequent cause of myocarditis in males. The murine 
CVB3 myocarditis model has a wide spectrum of disease severity, successfully 
recapitulating human viral myocarditis [80]. The presence of heart specific autoantibodies 
and myocyte-reactive T cells indicates the autoimmune nature of the disease [81, 82]. 
The initial hypothesis was that virus-mediated myocyte damage enables cardiac myosin 
to be exposed, which becomes readily accessible to the immune system. This hypothesis 
had led to the development of the EAM model, where genetically predisposed mice 
(typically BALB/c or A/J mice) are immunized with mouse cardiac myosin or peptides 
derived from heavy chain α emulsified in complete Freund’s adjuvant (CFA) 
supplemented with heat-killed Mycobacterium tuberculosis [80, 83] (Figure 1). On day 0, 
mice receive peptide emulsion subcutaneously together with an intraperitoneal injection 
of 500 ng of pertussis toxin. On day 7, mice receive a booster shot of peptide emulsion 
without pertussis [83]. It has been indicated that pertussis toxin can promote T cell 
proliferation and cytokine production as well as break T cell tolerance in an EAE model, 
though the precise mechanism underlying the role of pertussis toxin in EAM induction is 
not well understood [84]. In addition, substituting CFA for either incomplete Freund’s 
incomplete adjuvant or alum as the adjuvant on either day will not induce EAM, 
highlighting that a breakdown of immune tolerance is central for EAM induction [85].  
We used exclusively BALB/c male mice in our studies. They tend to develop myocarditis 
of moderate severity and progress to DCM. The induction phase of myocarditis is 
established by day 10, during which an adaptive immune response to cardiac myosin 
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develops. The acute phase of myocarditis begins between day 10-12, when immune cells 
start to infiltrate the myocardium. During this time autoantibodies emerge in the serum 
and autoreactive T cells can be detected in the heart. On day 21 post-immunization, the 
intensity of the immune infiltrate reaches its peak. The cell  number starts to decline 
thereafter, marking the beginning of myocarditis resolution phase. Occasionally chronic 
inflammation does not subside even after day 60 post-immunization. As cardiac immune 
cell infiltrates diminish, there is an increase in cardiac fibrosis and a decrease of 
ventricular functions that can be observed via histology and detected by 
echocardiography, respectively [56].  
 
Figure 1. Model of experimental autoimmune myocarditis in BALB/c mice experimental 
viral myocarditis 
 
D. Experimental viral myocarditis murine model 
CVB3 is an enterovirus that belongs to the Picornaviridae family [60]. CVB3 is implicated 
as one of the primary pathogens responsible for acute and fulminant viral myocarditis in 
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humans [86]. One of the most commonly used myocarditis mouse models is via CVB3 
infection to recapitulate viral myocarditis in humans [60]. Heart-passaged CVB3 virus 
(Nancy strain) are inoculated intraperitoneally into susceptible strains of mice. Acute 
myocarditis develops from day 7 to day 14 post-infection and progresses to DCM around 
day 35 post-infection [60]. A male gender bias in this model also replicates the human 
disease [87]. A recent study showed that sex hormones such as estrogen play a beneficial 





Monocytes and macrophages 
 
Monocytes and macrophages are highly conserved populations found in all vertebrates 
and play crucial roles in tissue homeostasis and protective immunity. Additionally, their 
roles in pathological processes such as myocarditis make them attractive therapeutic 
targets. However, the minimization of their pathogenic roles and maximization of their 
reparative functions during tissue injury requires an in-depth understanding of their origins, 
functions and interactions with the tissue microenvironments.   
 
A. Origins of tissue-resident macrophages 
Elie Metchnikoff was credited in 1882 for his seminal work describing phagocytosis, a 
process of phagocytes engulfing pathogens [89]. Macrophages are professional 
phagocytes that exist in all organs of the body as well as across diverse species. With the 
readily available techniques such as genetic fate mapping and lineage tracing our 
knowledge of macrophage role during disease and homeostasis has rapidly evolved over 
the past decade. We have gained an appreciation for the versatile roles and 
trophic/regulatory functions of macrophage in organogenesis, tissue homeostasis, 
immune surveillance, and post-injury tissue restoration [90]. During fetal organogenesis, 
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macrophages orchestrate long-distance communication between pigment cells in zebra 
fish skin to establish striped patterns [91]. They participate in synaptogenesis, synaptic 
pruning, neurogenesis and assembly of murine brain circuits [92-104]. In murine testes 
they contribute to testis morphogenesis, spermatogenesis, and production of male 
hormone during puberty [105-107]. They are indispensable in adult salamander limb 
regeneration [108].   
Before the term “mononuclear phagocyte system” (MPS) was coined in 1969 to describe 
the functions and morphology of monocytes, macrophages, dendritic cells, and their 
precursors from the bone marrow an older term, “reticuloendothelial system”, or RES, 
was used to describe these phagocytes and their antecedents. RES was based on the 
observation that sinus-lining intravascular phagocytes frequently form reticular networks. 
However, we now know that macrophages and endothelial cells are separate entities [109, 
110]. Macrophage phagocytosis is a process important for debris clearance and tissue 
remodeling. For instance, synaptic pruning by microglia eliminates defective and 
immature neuronal synapses during brain development [111]. While macrophage 
phenotypes are determined by tissue origin, an anti-inflammatory signature of high 
CD206 and low IL-1𝛽 expression can be unanimously elicited by phagocytic activity [112]. 
Additionally, macrophages are major cytokine producers that participate in innate and 
adaptive immune responses [113, 114].  
A growing body of literature has shown that adult murine tissue resident macrophages 
are mostly embryonically-derived, contradicting the long-held belief that macrophages are 
derived from circulating monocytes released from the bone marrow and spleen [115-119]. 
Surprisingly, discoveries made decades ago already acknowledged that yolk sac and fetal 
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liver of early embryos contained macrophage precursors [120, 121]. We now understand 
that during embryogenesis macrophages colonize developing organs in several 
overlapping waves [115-117] (Figure 2).  
The first wave of macrophage tissue colonization occurs at embryonic day 7 (E7), before 
the establishment of embryonic circulation [120, 122, 123]. Csf1r+c-Kit+CD45lowAA4.1+ 
Erythro-myeloid progenitors (EMPs) are released from yolk sac blood islands and 
capillary endothelia [124]. EMPs readily acquire macrophage transcriptional signatures 
and differentiate into pre-macrophages (pMacs) prior to seeding the tissue as resident 
macrophages (MØ) [116, 125, 126].  
From E8.5, a second wave commence as yolk sac hemogenic endothelia release another 
set of EMPs. The development of these EMPs relies on a master transcriptional regulator 
called c-Myb, whereas the EMPs from the first wave were c-Myb-independent [117, 127-
129]. At this stage of the embryonic development, the newly formed vasculature allows 
yolk sac macrophages to enter both brain and liver, as well as permit the EMPs derived 
from the second wave to seed the liver [122, 125, 130, 131]. EMPs expand rapidly in the 
fetal liver where they also differentiation into monocytic intermediates or pMacs at E11.5 
[117, 125, 131]. Both monocytic intermediates and pMacs then exit the fetal liver and 
seed all embryonic tissues with the exception of the brain [132]. These yolk sac-derived 
and fetal liver-derived tissue-resident macrophages persist into adulthood. Their renewal 
relies mostly on proliferation and minimally depends on replenishment by blood 
monocyte-derived macrophages [116, 118]. Skin and gut macrophages are exceptions in 
that they entirely depend on monocyte-derived macrophage replenishment to sustain the 
local macrophage pool [133, 134]. Lastly, the third wave of macrophage tissue 
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colonization occurs at E10.5, when hematopoietic stem cells (HSCs) derived from 
hemogenic endothelium in the dorsal aorta enter the fetal liver [115, 135, 136]. Upon entry, 
HSCs expand and differentiate into monocytic intermediates which then colonize the 
tissue to become resident macrophages [115, 137, 138]. HSCs also seed the bone 
marrow and spleen during embryogenesis to produce a constant supply of circulating 
monocytes postnatally to replenish macrophage pool in specialized organs under steady 
state or inflammation [119, 139]. A type of early pro-B cell that expresses both myeloid 
and lymphoid markers has recently been discovered as a progenitor for both tissue 




Figure 2. Macrophages colonize developing organs in several overlapping waves during 
embryogenesis.  
Figure drawn by X. Hou. 
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B. Heterogeneity of tissue macrophages 
A robust steady-state condition is required to ensure proper tissue function and maintain 
homeostasis of an organism. However, organ homeostasis varies considerably owning 
to differences in tissue metabolic and mechanical activities, physical barriers, the levels 
of exposure to commensals and nutrients, as well as maturation status. Most of the 
macrophages that populate tissues during organogenesis persist into adulthood as 
resident, self-maintaining populations in steady state [118, 141]. Tissue-resident 
macrophages hone their phenotypes in response to local microenvironmental signals and 
turnover in a tissue-specific manner (Figure 3). Central nervous system, epidermis and 
lung macrophages are exclusively yolk-sac and/or fetal liver derived. They have robust 
self-renewal potential and persist into adulthood under steady-state [142, 143]. These 
relatively ontogenically homogeneous populations can even cope with experimental 
depletion [144]. A small portion of liver Kupffer cells are derived from BM monocytes 
immediately after birth. They self-renew in adulthood without further contributions from 
monocytes [117, 145-147]. This is similar to arterial macrophages [148]. Cardiac resident 
macrophages consist of yolk-sac and fetal liver derived macrophages before birth [119, 
149]. Embryonically derived CCR2- macrophages are positioned near coronary 
vasculature, whereas fetal monocyte-derived macrophages tend to cluster near 
endocardial trabeculae [150]. This uneven distribution suggests their role in cardiac 
development. These yolk-sac-derived and fetal liver-derived macrophages are gradually 
replaced by monocyte-derived macrophages with age [149]. It has been demonstrated 
that at birth, almost all cardiac macrophages are CCR2-MHCII- (major histocompatibility 
complex class II). This relatively homogenous population diversifies into 4 subpopulations 
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with the increase of both CCR2 and MHCII expression [149]. Intestinal macrophages 
have a relatively short half-life (4 – 6 weeks). Both yolk sac-derived and fetal liver-derived 
macrophages begin to wane after birth in the lamina propria, and they require constant 
replenishment from BM-derived monocytes. This drastic replacement of embryo-derived 
macrophages by monocyte-derived cells coincides with commensal bacteria colonization 
and is highly depended on CCL2/CCR2 axis [139]. Similar to intestinal macrophage 
maintenance, dermal macrophages also rely on monocyte replenishment. They are 
thought to be highly phagocytic but are less sufficient in eliciting T cell activation [133]. 
The above evidence highlights the role of the tissue microenvironment in controlling 
macrophage origin and fate, as well as in determining monocyte recruitment and 
differentiation during steady-state. This remains an active area of research. Macrophages 
are highly adaptive. Their close association with the local habitat allows them to evolve 
and develop tissue-specific features defined by particular transcription factors and 
epigenetic marks [151-153]. Not surprisingly, when tissue macrophages are isolated to 
culture they rapidly lose tissue-specific phenotypes [152]. An example of how 
transcription factor influences tissue macrophage phenotype is Spi-C. Spi-C is crucial for 
maintenance of both splenic red-pulp macrophages and liver-resident Kupffer cells. 
These cells are positioned to engulf aging CD47- erythrocytes, which induce Spi-C to 
assist in heme-metabolizing processes [154]. Another example could be GATA-6 
expression in peritoneal macrophages of embryonic origin [155-157]. These cells are 
characterized as large F4/80hiMHCIIlo [158]. However, both retinoic acid and omental 
tissue-derived signals are needed for GATA-6 expression [156].  
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Macrophage functions vary widely depending on changes that occurring in its residing 
tissue niche including metabolites [152, 153, 159], intracellular metabolism [160], and 
genetic and intrinsic epigenetic factors [113, 161-163]. One of the most exciting advances 
in the field is the understanding of the epigenetic changes that characterize different 
population of tissue-resident macrophages. Although all immune cells share the identical 
genome, chromatin modification enables them to acquire distinct roles [164-168]. 
Particularly, comparison of the promoter and enhancer regions reveals that few 
macrophages are identical across different tissue microenvironments [153]. This 
demonstrates that local microenvironments imprint macrophages and creates 
heterogeneity within this population. Reciprocally, tissue macrophage expresses a variety 
of sensors located on the surface and inside the vacuoles and cytosol to provide contact 
and control to its residing environment. Since macrophages are prominent participants in 
disease pathologies, including heart failure, rheumatoid arthritis, multiple sclerosis and 
cancer, the study of chromatin landscape can identify targets for genetic manipulations 






Figure 3. Steady state macrophage origins in multiple adult tissues.  





Monocytes comprise approximately 4% and 10% of all circulating leukocytes in mice and 
in humans, respectively. There are two main monocyte subsets in mice, the “classical” 
Ly6ChiCCR2+CD62L+CX3CR1- inflammatory monocytes and the “alternative/non-
classical” Ly6CloCCR2-CX3CR1+ patrolling monocytes [169, 170]. The former is known to 
extravasate into tissue after an insult and release pro-inflammatory cytokines such as 
interleukin-1𝛽, tumor necrosis factor-𝛼, and reactive oxygen species. Ly6Chi monocytes 
also have a high tendency to differentiate and replace the diminishing tissue macrophage 
pool [169-173]. Ly6Clo monocytes are known to patrol the lumen of the vessels, 
scavenging for dead cells, oxidized lipids and pathogens [174]. Their differentiation into 
reparative macrophages has been reported in skeletal muscles and in soft tissue [175-
177]. In terms of phenotypes, function and gene expression profiles, human CD14hiCD16- 
and CD14+CD16+ monocytes account for about 90% of all circulating monocytes and 
resemble proinflammatory Ly6ChiCCR2+ monocytes in mice. Human CD14-CD16hi 
monocytes account for about 10% of the peripheral monocyte population and resemble 
patrolling Ly6CloCCR2- monocytes in mice [178-183]. 
 
D. Monocyte development 
The homeostatic production of monocytes requires defined developmental stages and 
commitment in the bone marrow (Figure 2, Table 3). Monocytes are heterogenous 
populations that originate from HSCs, and can also arise from fetal liver during 
embryogenesis (Figure 2). It has been demonstrated that the spleen harbors monocytic 
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precursors that can also contribute to monocytopoiesis during inflammation, a process 
termed “extramedullary hematopoiesis” [184]. HSCs, which represent about 0.05% of the 
adult mouse bone marrow population, are cells that possess multipotency and can self-
renew [185-189]. It has been shown that HSCs can give rise to long-term HSC (LT-HSC), 
short-term HSC (ST-HSC) and Multi-Potent Progenitors (MPP) (Figure 4). The latter two 
can no longer self-renew [190]. Lineage-restricted differentiation happens when MPP are 
produced. These MPPs then give rise to both common myeloid progenitors (CMP) and 
common lymphoid progenitors (CLP), which are both oligopotent progenitors (possessing 
relatively finite differentiation capacity) [191-194]. CMPs subsequently give rise to 
granulocyte and macrophage progenitors (GMP) and megakaryocyte/erythrocyte 
progenitors (MEP) [195, 196].  GMPs can further give rise to macrophage and DC 
precursors (MDP) [197], which are dedicated clonotypic precursors to common monocyte 
progenitor (cMoP) and common dendritic cells precursors (CDP) [198]. Common 
monocyte progenitors strictly generate monocytes, but not plasmacytoid DCs or cDCs 
[198]. Isolated cMoP can differentially give rise to both Ly6Chi and Ly6Clo monocytes [198]. 
On a molecular level, monocyte development is precisely controlled by lineage-defining 
transcription factors during each stage of development [199] (Figure 4). PU.1 or Sfpi1 
(also known as Spleen focus forming virus proviral integration oncogene) is critical in early 
steps of monocyte development, especially during the stage of CMP, GMP and MDP 
differentiations [200-202]. PU.1 knockout mice have an embryonic lethal phenotype or 
they die shortly after birth [203]. PU.1 binds to GATA-1 and inhibit CMP differentiation 




Figure 4. Monocyte development from the bone marrow.  




Another family of transcription factors known as C/EBP belongs to the basic leucine 
zipper family that recognizes and binds to DNA motif (5’-T(T/G)NNGNAA(T/G)-3’) [205, 
206]. While Cebpb is important for the development and maintenance of monocytes, 
Cebpa is important for monopoiesis [207-210]. Interestingly, Cebpa expression allows T 
and B lymphocytes to transdifferentiate into macrophages [211, 212]. IRF8 (interferon 
consensus sequence-binding protein) is another critical transcription factor required for 
monocyte development in the bone marrow. It is specifically induced in CMP and GMP 
[213]. IRF8 interacts with PU.1 to form heterodimers to regulate functions of both 
monocytes and macrophages [214]. IRF8 promotes monocyte differentiation and persists 
in differentiated monocytes and macrophages, whereas IRF8 subsides in granulocyte and 
inhibits their production [215]. IRF8 downstream directly regulates KLF4 (Kruppel-like 
factor 4), a key transcription factor for myelopoeisis [216]. KLF4 is indispensable for 
Ly6Chi monocyte development [217].  NR4A1 (Nuclear Receptor Subfamily 4, Group A, 
Member 1) is a master transcription factor required for Ly6Clo monocyte development, 
survival, and myelopoiesis [176, 218, 219].  
Finally, there are also a few negative regulators of monocyte production. The lack of either 
GATA-2, Fli-1 (Friend leukemia integration 1) or RUNX1 (RUNT-related transcription 
factor 1) leads to upregulation of monocyte production and release [220-226]. Other 
factors also play a role in monocyte development. Colony-stimulating factor 1 (M-CSF) is 
indispensable for monocytes survival and development in mice. Animals deficient in M-
CSF or M-CSF receptors (CD115 or M-CSFR) such as op/op mice suffer from severe 
monocytopenia [227-229]. M-CSF is also involved in tissue-resident macrophage 
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proliferation and survival by apoptosis reduction [155, 230, 231]. CX3CR1 is also 
important to promoting long term survival in monocytes [232]. 
During steady state, monocytes are released from the BM with a regular circadian rhythm 
associated with regulatory genes such as Bmal1, Nrld1 and Dbp. Blood monocytes’ 
diurnal rhythm peaks at Zeitgeber times (ZT) 4 and reaches nadir at ZT 16 [233]. The 
fluctuation of blood monocytes is also important in determining mortality and morbidity 
after myocardial infarction (MI), which will be discussed at a later chapter [234]. 
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Chapter 3: 
Monocytes and macrophages in cardiovascular disease 
 
 
A. Monocytes and macrophages in Heart Failure (HF) 
 
An estimated 26 million people are affected by HF worldwide and its prevalence is 
projected to continue to increase [240]. HF adversely affects quality of life and reduces 
the overall lifespan [241]. The pathological signs of HF are progressive impairment of 
cardiac function with many patients developing atrial fibrillation [242]. Globally, rheumatic 
heart disease remains a major cause for HF. Cardiac inflammation from rheumatic 
disease results in scarring of the heart valves, primarily the mitral valve, with consequent 
valvular malfunction and HF [243]. In developed nations myocardial infarction (MI) is the 
leading cause of HF [244]. MI is typically the result of atherosclerotic plaque rupture and 
coronary occlusion [242]. Murine models have helped to demonstrate that both 
monocytes and monocyte-derived macrophages play a pivotal role in the pathogenesis 
of MI. It is thought that monocyte subsets are designated to perform distinct but complex 
roles that may be beneficial or detrimental [245-247]. Although studies are limited in 
human subjects, it has been shown that there is a post-infarction increase in the total 
number of blood monocytes and this correlates with an increased left ventricular end-
diastolic volume and a decreased ejection fraction [248].  
Under steady state, resident cardiac macrophages in healthy adult mice represent less 
than 10% of the total non-cardiomyocyte population [249]. However, cardiac ischemia 
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from MI drives hematopoiesis that mobilizes immune cells, including pro-inflammatory 
monocytes, to enter the infarct zone and differentiate into macrophages [171, 250]. When 
diurnal monocyte fluctuation is disrupted, myocardial remodeling and function worsen in 
post-infarct mice [234]. The observation of diurnal variation extends to human subjects 
with MI who manifest increased ST-segment elevations that correlate with peaking of their 
infarct size at 1:00 in the morning [251]. Furthermore, it is thought that sequential 
recruitment of Ly6Chi and Ly6Clo monocytes to the infarct zone regulates the inflammatory 
and reparative response post-infarct, respectively [245]. However, the exact function of 
Ly6Clo monocytes is unknown. It has been shown that the orphan nuclear receptor 
NR4A1 controls BM differentiation and survival of the Ly6Clo monocytes, since Ly6Clo 
monocytes are absent from Nr4a1–/– mice [218]. Nr4a1 was proposed to be an important 
factor required for Ly6Chi monocytes to differentiate into reparative macrophages [171].  
B cells in post-infarct myocardium are thought to also play a role in monocyte recruitment. 
They are thought to predominantly produce CCL7, a ligand for CCR2. B cell depletion, 
therefore, results in reduced monocyte trafficking and improved ventricular function [252]. 
Neutrophils, on the other hand, produce gelatinase-associated lipocalin to promote a 
reparative phenotype in macrophages which is beneficial in infarct healing [253]. 
Monocyte and macrophage activation potentiates the cardiac inflammatory response by 
exerting a wide range of functions. They are thought to promote myofibroblast 
accumulation, collagen and extracellular matrix deposition, phagocytosis and 
angiogenesis, all of which promote myocardium remodeling post infarct [254].  
CCR2+ macrophages, in particular, have the capacity to produce large amounts of pro-
inflammatory cytokines [119]. CCR2 blockade or deficiency reduces inflammation and 
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cardiac fibrosis without changing hypertrophy outcomes in a model of pressure overload 
[255]. Ischemic injury results in rapid accumulation of dying myocytes [256]. Paradoxically, 
phagocytosis of dead cell and matrix debris triggers an anti-inflammatory profile in 
macrophage subsets [257]. As a result, macrophage depletion during infarct healing 
jeopardizes proper repair and increases mortality [258, 259]. Therefore, monocytes and 
macrophages are also indispensable in tissue remodeling post-infarct [250, 260, 261]. It 
was demonstrated that a significant macrophage expansion occurs between 4 to 8 weeks 
post MI in the remote non-infarcted myocardium [262, 263]. Fate mapping studies showed 
that this macrophage expansion results from both CCL2 (C-C chemokine receptor type 
2) dependent monocyte recruitment and local macrophage proliferation [262]. The 
inhibition of monocyte infiltration at late time-points in non-infarct areas significantly 
reduced adverse remodeling, indicating that monocyte-derived macrophages in the non-
infarct myocardium play a role in aggravating post-infarct heart failure [262]. It has been 
proposed that higher diastolic pressure in the left ventricle creates a cytokine environment 
that drives similar macrophage expansion in humans as well [262]. 
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of 
the patients suffering from HF [264]. HFpEF has been increasing in prevalence due to 
increasing extracardiac comorbidities such as hypertension, diabetes and obesity [265, 
266]. Although the high mortality and morbidity for HFpEF make it a significant clinical 
problem, there is no treatment currently available [265, 267]. Despite significant 
cardiomyocyte death, HFpEF has a relatively normal systolic contraction. The 
pathophysiology of HFpEF includes diastolic impairment and chronotropic incompetence 
[268]. Chronotropic incompetence is the inability of the heart to increase its rate to 
 28 
compensate for strenuous activities [269]. A recent study showed that mice receiving salty 
drinking water, unilateral nephrectomy, and chronic exposure to aldosterone (SAUNA) 
developed hypertension and HFpEF similar to human patients [270]. An expansion of the 
macrophage population was found in both mice and humans when compared to healthy 
controls. These murine MHCIIhi macrophages produce IL-10 as an autocrine factor. 
Macrophage specific depletion of IL-10 ameliorates fibrosis and diastolic function [270]. 
IL-10 producing macrophages are also active during the reparative phase post-MI to 
promote scar formation through myofibroblast activation and proliferation [271].  
Because exacerbated monocytosis in the damaged heart impairs the post-infarct healing 
process, there are several proposed methods to curb monocyte recruitment. First would 
be the reduction of HSC egress from the BM. It was shown that 𝛽3-adrenoreceptor 
blockade in ApoE–/– mice post-infarct reduced monocytosis [272]. Second would be the 
reduction of extramedullary monocytosis from the spleen. Disruption of angiotensin II-
angiotensin 1 receptor signaling can potentially inhibit monocytes’ release from spleen 
[273, 274]. Lastly, would be the reduction of monocyte recruitment to the infarct. CCR2 
knockdown decreased proinflammatory monocytes trafficking that improved proper 
infarct healing [275, 276]. And the treatment of Irf5 siRNA nanoparticle delivery to the 
heart has been proposed to reduce myelotropic chemokine production and overall 
inflammation in mice post-infarct [277, 278].  
Notably, it has been recently proposed that macrophage immunometabolism could be a 
promising HF therapeutic target. Changes in metabolic states dictate macrophage pro- 
and anti-inflammatory functions [279-281]. Engulfed apoptotic cells generate metabolites 
that downstream promote a reparative phenotype in macrophages [281].  
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B. Monocytes and macrophages in Atherosclerosis 
Atherosclerosis is one of the leading causes of death in Western society and is associated 
with a number of risk factors such as obesity, insulin resistance, smoking and physical 
inactivity [282, 283].  Atherosclerosis is a chronic arterial inflammatory disease, triggered 
by apolipoprotein-B-containing lipoproteins (apoB-LPs) retained inside the subendothelial 
space called the intima [284]. ApoB-LPs consist of a neutral lipid core, composed 
predominantly of cholesteryl fatty acyl esters and triglycerides, enclosed by a monolayer 
phospholipids and proteins. There are two types of apoB-LPs: hepatic and intestinal. 
Hepatic apoB-LPs are circulating low-density lipoprotein (LD) and the intestinal apoB-LPs 
are remnant lipoproteins; both are highly atherogenic [283]. Retention of apoB-LPs 
predominantly occurs at arterial branch points and bifurcations that leads to disturbed 
laminar flow [285, 286]. Although normally this retention is benign due to preservation of 
the arterial lumen, a vulnerable plaque containing a necrotic core can lead to major 
problems. A local occlusive luminal thrombosis can form in patients with ruptured or 
eroded large arterial atherosclerotic plaques, which are likely to result in acute MI, stroke 
or sudden cardiac death [287, 288] (Figure 5). The extent of apoB LP retention is 
determined by multiple factors, including peripheral apoB LP concentration, age and 
genetic background of the individual [289]. Additional risk factors such as hypertension, 
diabetes, obesity, rheumatoid arthritis and psoriasis can also accelerate atherosclerosis 
progression [287].  
While a good deal of the information that we have on the pathogenesis of atherosclerotic 
lesions has been derived from murine models, it is important to note that the 
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atherosclerotic mouse models only partially recapitulate human disease. There are 
currently two widely used murine models: high fat, Western diet fed Ldlr–/– mice and chow 
fed or Western diet fed Apoe–/– mice [290]. Although neither model sufficiently replicates 
human plaque rupture and acute luminal thrombosis, the preponderance of evidence 
provided by mouse models indicated that monocyte and macrophages play a decisive 
role in atherosclerosis development in both humans and mice [291].  
The number of circulating inflammatory monocytes (CD14+ in human and Ly6Chi in mice) 
is positively correlated with atherosclerosis [292, 293]. It has been shown that these 
circulating inflammatory monocytes are tethered to activated endothelial cells and migrate 
to the intima and differentiate into inflammatory macrophages [294, 295]. However, one 
study has shown that Ly6Chi monocytes can also contribute to anti-inflammation 
macrophages during plaque regression [296]. It is unclear whether Ly6Clo monocytes are 
capable in becoming macrophages [297]. Nevertheless, when blood monocyte 
recruitment to the plaque is inhibited, lesion formation is markedly decreased [298]. Tacke 
and colleagues have shown that maximal suppression of atherogenesis can only be 
achieved by blockade of both Ly6Chi and Ly6Clo monocytes trafficking to the 
atherosclerotic plaques [299].  
It has been reported that monocyte-derived macrophages together with local proliferating 
resident macrophages are the most predominant populations within the plaque [300, 301]. 
Macrophages contribute to plaque growth and apoB-LP retention by either engulfing 
oxidized low-density lipoprotein particles (oxLDL) to become foam cells, or secreting 
proteoglycans that bind to apoB-LP [286]. Notably, the two most important changes 
mediated by pro-inflammatory monocytes/macrophages are plaque necrosis and 
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weakening of the protective fibrous cap, which ultimately leads to lesion rupture (Figure 
5). It has been demonstrated that a combination of macrophage apoptosis and defective 
macrophage efferocytosis functions contribute to plaque necrosis in advanced 
atherosclerosis [302, 303]. Several mechanisms that lead to inefficient efferocytosis were 
proposed including oxidative stress as a result of defective cholesterol efflux or proteolytic 
cleavage of MerTK efferocytosis receptor [304, 305]. Moreover, macrophage-derived 
matrix metalloproteinases (MMPs) have been shown to contribute to fibrous cap thinning, 
particularly MMP2, MMP9, MMP13 and MMP14 [306-308]. A separate pathway has been 
described that macrophages can trigger the apoptosis pathway of the smooth muscle 
cells through Fas and Fas ligand interactions as well as TNF𝛼 and nitric oxide production, 
which also increase plaque vulnerability [309]. Conversely, anti-inflammatory 
macrophages are crucial in stabilizing plaque by engulfing debris to prevent plaque 
necrosis and producing collagen to strengthen the fibrous cap [289, 310]. Both pro- and 
anti-inflammatory macrophages are present in human atherosclerotic lesions [311]. In 
addition, increased sympathetic nervous system activity was found to worsen 
atherogenesis post-infarct by promoting hematopoietic stem and progenitor cells (HSPCs) 
to egress from the BM [272]. These HSPCs seed the spleen and contribute to the increase 
in blood Ly6Chi monocytes number through extramedullary hematopoiesis [184].  
Monocyte-derived macrophages produce significant levels of IL-1β in the failing heart. 
Antibody or targeted gene therapies used to prevent monocyte entry into atherosclerosis 
lesions ameliorate disease progression in mice [283, 295]. In clinical settings, neutralizing 
immune cell functions using anti-IL-1β has resulted in improving atherosclerosis 
outcomes despite some adverse effects in the Canakinumab (a human anti-IL-1β 
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monoclonal antibody) anti-inflammatory thrombosis outcomes study (CANTOS) [312]. 
The study concluded that anti-IL-1β not only reduces monocyte entry into lesions but also 






Figure 5. Manifestations of atherosclerosis arise when fibrous cap thins and plaques 
undergo rupture.  
Figure drawn by X. Hou. 
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Chapter 4: 
Monocytes and macrophages in autoimmune disease 
 
 
Autoimmunity reflects dysregulation of host tolerance. Dysfunction in central tolerance 
predisposes autoimmunity and faulty peripheral tolerance unleashes autoimmune 
disease pathology. Otherwise speaking, a defective immune system that cannot 
discriminate self from non-self is the basis for autoimmune diseases [315]. In order to 
maintain tolerance, self-reactive lymphocytes must be eliminated, sequestered, or 
silenced in a timely manner. The presence of autoantibodies is an important serological 
feature of autoimmune diseases and signals the breakdown of immune tolerance. Central 
tolerance, peripheral anergy, and secretion of regulatory cytokines/chemokines by T 
regulatory and key innate cells are essential components needed to maintain immune 
tolerance [316]. Autoimmune diseases encompass nearly 100 types of disorders and 
affect about 5% of the population in the Western hemisphere [315, 316]. Despite recent 
advances in the diagnosis and the treatment of the symptoms of autoimmune diseases, 
both mortality and morbidity in affected populations remain high. Monocytes and 
macrophages have been implicated in the pathogenesis of several autoimmune diseases 
including myocarditis, DCM, systemic lupus erythematosus (SLE), multiple sclerosis (MS), 
inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). 
Macrophages function as phagocytes that recognize and sequester foreign agents and 
apoptotic debris [317]. They are also capable in secreting cytokines and chemokines as 
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paracrine factors that modulate activities of other cells [317]. Macrophages can act as 
potent antigen presenting cells that instigate adaptive immune responses [317]. 
Additionally, macrophages are known to promote angiogenesis and fibrosis during tissue 
injury [318]. Macrophage subsets are highly diverse with regard to their ontogenies, 
phenotypes and functions (see above). It has therefore been challenging to decipher their 
role during autoimmune pathogenesis. However, current advances in lineage tracing and 
fate mapping allow us to distinguish monocyte-derived from embryo-derived 
macrophages in different tissues and organs.  
 
A. Monocytes and macrophages in multiple sclerosis (MS) 
Multiple sclerosis (MS) is a neurodegenerative autoimmune disorder affecting 
approximately 2.5 million young adults worldwide [319, 320]. It is characterized by axonal 
and neuronal loss as a result of chronic inflammation and demyelination in the central 
nervous system (CNS). Macrophages and resident microglia comprise the predominant 
pathogenic leukocytes present in the CNS during disease development, followed by CD4+ 
T cells, likely as a result of breakdown of the blood-brain barrier [321-324]. Like many 
other autoimmune diseases, MS is the result of a combination of genetic predisposition 
and environmental influences. Genome-wide association studies (GWASs) have 
identified more than 230 genetic variants that increase disease susceptibility for MS [325-
327]. A significant expansion of peripheral blood nonclassical CD16+CD14- monocytes 
was observed in patients with MS compared to healthy controls [328]. This observation 
coincides with similar nonclassical monocyte expansion in psoriasis, rheumatoid arthritis 
and other autoimmune disorders [329, 330]. Experimental autoimmune encephalomyelitis 
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(EAE) is one of the most well characterized animal models of MS disease [331]. EAE can 
be induced by either immunization with myelin peptide emulsified in CFA or adoptive 
transfer of encephlitogenic T cells [332, 333]. The former model requires pertussis toxin 
injection to induce EAE in susceptible strains of mice [333]. Although EAE is associated 
with encephalitogenic lymphocyte mediated demyelination, monocyte infiltration into the 
CNS is correlated with EAE initiation and the progression of paralysis [334-337]. It has 
been shown that monocyte-derived macrophages mediate myelin destruction, whereas 
microglia-derived macrophages are required for debris clearance [338]. Recently it has 
been shown that the receptor for tumor necrosis factor, TNFR2, plays a dichotomous role 
in the regulation of EAE pathophysiology. Specifically, TNFR2 promotes microglia 
activation and proliferation, which in turn provides anti-inflammatory signals to suppress 
neuroinflammation, whereas TNFR2 signaling in monocytes and monocyte-derived 
macrophages is detrimental, driving immune activation and EAE initiation [339].  
 
B. Monocytes and macrophages in rheumatoid arthritis (RA) 
Rheumatoid arthritis (RA) is a chronic autoimmune joint disease. Inflammatory 
pathology is localized in the synovium of multiple joints. Cartilage and bone damage 
results when RA is left untreated [340]. Macrophages are known to play a crucial role 
in the pathogenesis of rheumatoid arthritis (RA) by augmenting and orchestrating a 
pro-inflammatory environment. An increased number of synovial macrophages 
correlates with the cartilage and bone destruction that results in joint erosion [341]. 
Depletion of Synovial macrophages has offered tremendous therapeutic benefit in 
animal models of RA [341, 342]. An early hallmark of active rheumatic disease is an 
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increase number of HLA-DR+ macrophages in both the lining and sub-lining synovial 
membranes [341]. Synovial lining consists of tissue-resident macrophages and 
fibroblasts, whereas the synovial sub-lining (beneath synovial lining and facing synovial 
fluid) consists of infiltrating monocyte-derived macrophages, fibroblasts, scattered 
blood vessels and fat cells [341, 343]. An early hypothesis stated that macrophages 
initiate RA through antigen presentation to infiltrating T cells, similar to disease 
mechanism proposed for Graves’ disease and type 1 diabetes mellitus [344]. The 
development of anti-TNF treatment for RA and other diseases represents a major 
clinical effort to downregulate HLA expression and inhibit excessive TNF production by 
macrophages [345, 346]. So far the origin of resident synovial macrophages is not well 
understood. Phenotypic differences between synovial lining macrophages and 
cartilage junction macrophages were reported in patients with RA [347]. However, there 
is no obvious evidence indicating macrophage polarization in the inflamed joints, 
although higher TNF and IL-1 and lower IL-10 suggest enhanced M1 activities in 
patients with RA [348]. 
The K/B x N serum-transfer mouse model of sterile inflammatory arthritis is used to 
mimic the effector phase of human RA [349]. This model allowed researches to 
conclude that Ly6C lo monocytes are able to differentiate into MHCII+ macrophages 
during effector stage after recruitment to drive disease pathology [350]. This is distinctly 
different from MHCII- tissue-resident synovial macrophages, which were thought to limit 
arthritis development [350]. 
An antigen-induced arthritis (AIA) model has been developed to recapitulate both the 
induction and effector phase of human RA [349]. CFA induces systemic inflammation, 
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which promotes predominantly Ly6Chi monocytes to infiltrate the knee and differentiation 
into macrophages [351].  
The model that most closely resembles human RA is collagen-induced arthritis (CIA). The 
breakdown of immune tolerance, release of autoantibodies, and excessive pro-
inflammatory cytokine release are all indispensable components in this model [349]. 
Multiple studies have concluded that Ly6Chi monocyte are pathogenic in this model [352-
354]. CD14+CD16+ intermediate human blood monocytes were more elevated in RA 
patients than in healthy controls [355]. These monocytes are thought to possess a potent 
ability to secrete inflammatory cytokines [356]. Therefore, we must be extremely cautious 
when proposing macrophage targeted treatment for RA patients since as yet there is no 
consensus regarding which exact populations are important in RA pathology. In addition 
to many proposed cytokine inhibitory treatments, nanoparticle delivery of Irf5 siRNA has 
been proposed [277]. IRF5 is a transcription factor important for monocyte differentiation 
into MHCII+ macrophages, as well as GM-CSF and CXCL1 release [351, 357].  
 
C. Monocytes and macrophages in inflammatory bowel disease (IBD) 
Inflammatory bowel diseases (IBDs) are chronic relapsing disorders of the 
gastrointestinal (GI) track due to environmental perturbation and genetic predisposition. 
More specifically, it is due to the failure of the immune system in the GI track to maintain 
its balance between keeping harmful pathogens at bay while retaining tolerance to the 
commensal microbiota [358]. There are two main forms of IBDs, Crohn’s disease (CD) 
and ulcerative colitis (UC) [359]. 
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Monocyte-derived Ly6CloCX3CR1hiMHCIIhi intestinal resident macrophages make up 
the largest tissue-associated macrophage population in the body. They are essential in 
protecting the host against opportunistic pathogens as well as maintaining GI 
homeostasis [358, 360, 361]. In mice, the half-life for intestinal resident macrophages 
is approximately 3 to 5 weeks [362]. Therefore, Ly6ChiCX3CR1loMHCIIlo monocytes are 
thought to be the precursors that continuously replenish the intestinal macrophage pool 
after birth [358]. The majority of intestinal macrophages are strategically positioned in 
the lamina propria beneath of the epithelium surface as sentinels [360]. Because these 
intestinal tissue macrophages express high levels of MHCII, they are thought to play a 
role in Foxp3+ T regulatory cell maintenance in the lamina propria [363]. Similarly, these 
macrophages support generation of commensal-specific Th17 cells, which are key 
immune cells that support barrier integrity [364, 365]. Apart from performing phagocytic 
housekeeping functions, intestinal resident macrophages also produce prostaglandin 
E2 to support epithelial integrity [366-368]. Furthermore, they are known to support 
peristalsis by interacting with enteric neurons [369]. The intestinal mucosa induces 
intestinal macrophages to constitutively produce anti-inflammatory cytokines such as 
IL-10 which act as an autocrine factor that dampens macrophages’ pro-inflammatory 
responses and excessive activation [368, 370-375]. Chronic inflammation such as IBD 
has a profound impact on tissue macrophage compartments. There are two subsets of 
macrophages in the inflamed gastrointestinal track that exhibit vastly different functions, 
CX3CR1hi resident and CX3CR1int inflammation-elicited intestinal macrophages [134, 
370]. CX3CR1int macrophages exhibit a pro-inflammatory signature and are thought to 
be pathogenic in the colitis mouse model [134, 376]. The current hypothesis is that the 
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local microenvironment, which is critical for instructing Ly6Chi monocytes to become 
anti-inflammatory CX3CR1hi macrophages, is instead arresting the monocyte 
differentiation pathway [134, 370]. As a result, during the resolution of inflammation, 
CX3CR1int macrophages are removed from the microenvironment, possibly due to 
apoptosis or through differentiation into resident macrophages [134, 366, 377]. The 
present knowledge about intestinal macrophages is predominantly generated through 
murine models; studies in human subjects are sparse. While CD results from impaired 
bacterial clearance by macrophages, UC results from heightened response against 
bacteria [378, 379]. Overall, intestinal CD14hi mononuclear phagocytes are markedly 
increased in IBD patients [380, 381]. These pro-inflammatory CD14hi cells produce high 
levels of IL-6, IL-23, TNF-𝛼 and IL-1𝛽 but not IL-10 [382, 383]. Although the overall 
macrophage numbers are similar between CD and UC patients, it is thought that the 
composition and function of intestinal macrophages differ greatly [384]. For example, 
CD patients develop more fibrosis in the GI track than UC patients [385-387]. Tissue 
fibrosis has been shown to be closely associated with macrophage-mediated excessive 
wound healing. MMP-2 produced by macrophages to breakdown extracellular matrix 
has been shown to increase in CD patients’ mucosa relative to healthy controls [388, 
389]. Taken together, the involvement of macrophage subsets in the pathogenesis of 
UC and CD needs to be further elucidated to establish clinical relevance. 
 
 
D. Monocytes and macrophages in systemic lupus erythematosus (SLE) 
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In patients with Systemic lupus erythematosus (SLE), the continuous production of a wide 
array of autoantibodies ensures chronic inflammation and tissue damage in multiple 
organs [390]. It is increasingly recognized that aberrations of monocytes and 
macrophages are the basis of the pathogenesis of SLE in both mice and humans [391, 
392]. Uptake of apoptotic and necrotic debris by macrophages through phagocytic 
processes is essential in maintaining homeostasis. Ineffective phagocytosis enables 
exposure of autoantigens that triggers autoimmune responses [391]. It has been 
documented that patients with SLE have defective macrophages that are incapable of 
apoptotic cell clearance compared to the control patients [393, 394]. More recent studies 
have demonstrated that sera from SLE patients possess apoptosis-inducing-properties 
and SLE patients’ lymph nodes have increased accumulation of apoptotic cells and 
decreased presence of phagocytic macrophages [395, 396]. Phagocytic defect is then 
compounded by chronic inflammation, which further drives SLE pathology [397]. However, 
it is currently unknown whether such a phagocytic defect is inherent or modulated by the 
environment.  
Due to the highly heterogeneous nature of human SLE, no mouse model can completely 
recapitulate the broad spectrum of disease presentations in human subjects [398, 399]. 
Although the mouse models of SLE (Table 4) have contributed significantly to a better 
understanding of disease development and treatment, most studies have focused on 
lymphocytic involvements in lupus rather than that of myeloid cells [400, 401]. To improve 
the effectiveness of murine models, the latest technologies for genetic studies will include 
use of the CRISPR/Cas9 system, which allows for rapid assessment of the genetic impact 
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on lupus development [402]. Furthermore, humanized mice are being developed to bridge 
the gap between mouse model and human disease [403, 404].  
Monocytes and macrophages are key components involved in the regulation of numerous 
diseases that are inflammatory or autoimmune in nature. The roles of these cells in the 
pathogenesis of myocarditis and DCM is still unclear. We hypothesize that the functions 
of monocytes and macrophages are driven both by endogenous and by exogenous 
factors in the heart during myocarditis development. We speculate that the fates and 
functions of the myocardial infiltrating cells determine the outcomes of DCM. In chapter 
5, we will discuss the background of our work, our core findings, and discussing the 






















NZB/NZWF1 (BW)  
[405] 
Produce autoantibodies (predominantly ANA and anti-
dsDNA) and develop immune complex glomerulonephritis 
and mild vasculitis. This model does not recapitulate the full 
spectrum of SLE manifestation in human and disease 
development is slow [406].  
 
NZM2410 [407] Produce autoantibodies and develop immune complex 
glomerulonephritis only. Used extensively to define genetics 
of lupus [407, 408]. 
 
NZM2328 [409] Produce autoantibodies and develop acute 
glomerulonephritis followed by chronic nephritis [410, 411]. 
 
MRL/lpr [412] Develop a full spectrum of autoantibodies (anti-Sm, anti-Ro, 
anti-La, ANA and anti-dsDNA), as well as involves multiple 
organs including arthritis, skin rash and cerebritis [413, 414].  
 
BXSB [415, 416] SLE only occur in male mice. Produce autoantibodies and 
develop immune complex glomerulonephritis only [415, 416]. 
 
SNF1 [417] Produce autoantibodies and develop immune complex 









Induce over-production of type I IFNs, similar to human SLE 
[419]. Produce many types of autoantibodies and develop 




induced [421, 422] 
Induce over-production of type I IFNs in only BALB/c strain. 
Produce autoantibodies, develop immune complex 




Depend on the strain used, autoantibodies and immune 
complex nephritis can be induced [423]. 
 
Antibody induced The injection of anti-glomerular basement membrane 
antibodies can induce rapid onset immune complex 
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Two types of monocytes, Ly6Chi and Ly6Clo, infiltrate the heart in murine experimental 
autoimmune myocarditis (EAM). We discovered a previously unappreciated role for 
cardiac fibroblasts in facilitating monocyte-to-macrophage differentiation of both Ly6Chi 
and Ly6Clo cells, allowing these macrophages to perform divergent functions in 
myocarditis progression. During the acute phase of EAM, IL-17A is highly abundant. It 
signals through cardiac fibroblasts to attenuate efferocytosis of Ly6Chi monocyte-derived 
macrophages (MDMs) and simultaneously prevents Ly6Clo monocyte-to-macrophage 
differentiation. We demonstrated an inverse clinical correlation between heart IL-17A 
levels and efferocytic receptor expressions in humans with heart failure. In the absence 
of IL-17A signaling, Ly6Chi MDMs act as robust phagocytes and are less pro-
inflammatory, whereas, Ly6Clo monocytes resume their differentiation into MHCII+ 
macrophages. We propose that MHCII+ Ly6Clo MDMs are associated with the reduction 
of cardiac fibrosis and prevention of the myocarditis sequalae.  
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Myocarditis remains a leading cause of heart failure in children and young adults [426, 
427]. A recent global estimate of myocarditis incidence is approximately 1.5 million cases 
annually [428]. However, the actual myocarditis incidence could be significantly 
underestimated due to the heterogeneous clinical manifestations and a wide spectrum of 
disease presentations [429]. Between 9-16% of patients with myocarditis develop dilated 
cardiomyopathy (DCM). Yet no biomarkers are currently available to identify myocarditis 
patients at risk of developing DCM [57, 430, 431]. To date, treatment of myocarditis and 
prevention of its sequelae, DCM, remain vital goals in the quest to reduce morbidity and 
mortality in patients.  
 
In the experimental autoimmune myocarditis (EAM) model as well as human clinical 
studies, we and others have reported that monocytes and macrophages comprise 
approximately three quarters of the infiltrating cells in the injured myocardium [432, 433]. 
Cardiac tissue-resident macrophages originate from precursors that develop in the 
embryonic yolk sac and fetal liver and maintain locally as self-renewing populations to 
perform tissue-specific functions. After birth, a proportion of embryonically-derived 
cardiac resident macrophages are progressively replaced by monocyte-derived 
macrophages (MDMs) that originate in the bone marrow (BM) [116, 118, 119, 147, 149, 
434]. BM-derived circulating monocytes in mice consist of two subsets: the ‘classical’ 
inflammatory Ly6Chi monocytes and the ‘non-classical’ patrolling Ly6Clo monocytes. The 
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former resemble human CD14hiCD16– and/or CD14+CD16+ monocytes, while the latter 
has similar characteristics to human CD14–CD16hi monocytes [169, 170, 176, 317, 435-
438]. Cardiac injury triggers massive Ly6Chi monocytes mobilization, trafficking and 
extravasation into the heart where they promote inflammation associated with tissue 
repair and remodeling [119, 171, 184, 272, 439-441].  
 
It is challenging to distinguish tissue-resident macrophages from recruited MDMs when 
they co-exist in the same inflammatory niche. It is known that Ly6Chi monocytes are 
precursors to cardiac macrophages during cardiac injury [119, 245]. However, whether 
patrolling Ly6Clo monocytes also contribute to the macrophage pool is controversial. 
Ablation of Ly6Clo monocytes in a mouse model of myocardial infarction (MI) resulted in 
depletion of other monocyte and macrophage populations [245]. Moreover, it is unclear 
whether the phenotype and function of either Ly6Chi or Ly6Clo MDMs differ from one 
another. The mechanism through which extrinsic stimuli influence monocytes survival, 
proliferation, differentiation and function in the context of cardiac damage and 
inflammation is not understood. 
  
We previously identified an important role of IL-17A in driving myocarditis progression to 
DCM [442]. IL-17A-deficient or IL-17 receptor alpha (IL17Ra)-deficient mice developed 
myocarditis with similar severity as WT animals. Remarkably, they have preserved 
cardiac functions and were protected from myocardial fibrosis and DCM [442]. We also 
reported that anti-IL-17A treatment during EAM onset can prevent DCM development in 
WT mice [442]. IL-17A signaling to cardiac fibroblasts results in the induction of 
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granulocyte-macrophage colony-stimulating factor (GM-CSF) and CCL2, which drives 
Ly6Chi monocyte chemotaxis and accumulation in the heart, worsening DCM outcomes 
[247, 442]. The pathogenic role of IL-17A in the development of cardiac fibrosis and heart 
failure has also been confirmed in MI (Chen et al, 2018).  
 
In order to better understand the underlying mechanisms of how recruited monocytes 
drive DCM, we fate-mapped the accumulating monocyte subsets in the heart during 
myocardial inflammation. We found that IL-17A-activated cardiac fibroblasts significantly 
arrested Ly6Clo monocyte-to-macrophage differentiation and proliferation. We also 
discovered that IL-17A signaling through cardiac fibroblasts can downregulate 
efferocytosis receptors expressed by Ly6Chi MDMs, negatively affecting their phagocytic 
function during inflammation resolution. Furthermore, both intrinsic and extrinsic factors 
modulate distinct transcriptomic profiles of Ly6Chi and Ly6Clo MDMs, signifying their 
potential functional differences in the context of myocarditis. Our work provides evidence 
that cardiac fibroblasts play a decisive role in MDM ontogeny and function during cardiac 
injury. Our findings provide new insights into monocyte and macrophage biology and their 





Infiltrating monocytes contribute to three subsets of macrophages during myocarditis 
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We created parabiotic mice to elucidate the contribution of infiltrating monocytes to 
cardiac macrophage populations under the influences of an inflammatory 
microenvironment during myocarditis development. The circulations of CD45.1 and 
CD45.2 mice were surgically joined, EAM was induced in CD45.1 mice 2 days prior to 
parabiosis (Figure 6A). On day 21 of EAM, we confirmed by histology that only CD45.1 
parabionts developed severe myocardium infiltration (Figure 6B). Flow cytometric 
analysis at day 21 showed a significantly elevated total number of infiltrating non-
neutrophilic myeloid cells in the CD45.1 EAM hearts compared to their CD45.2 parabiotic 
partners (Figure 6C). We also observed that CD45.1 EAM hearts had more total 
F4/80hiCD64+ macrophages compared to non-EAM CD45.2 hearts, indicating cardiac 
macrophage expansion in response to inflammation (Figure 6D). We found a higher 
frequency of CD45.2+ MDMs in the CD45.1 EAM mice, compared to CD45.1+ MDMs in 
the CD45.2 non-EAM mice (Figure 6E, F; see gating strategy in Figure 7A). However, a 
higher frequency of CD45.2+ MDMs in the CD45.1 EAM mice did not reflect a higher 
frequency of total CD45.2+ infiltrating monocytes (Figure 6E). In addition, Ly6Chi to Ly6Clo 
monocyte ratio in the hearts between parabionts did not differ significantly (Figure 6G). 
Resident tissue macrophages can be further divided into three subsets, based on their 
expression of CCR2 and MHCII [119]. We found that infiltrating CD45.2+ monocytes 
predominantly differentiated into CCR2+MHCII+ macrophages, though they possess the 
capacity to replenished all three macrophage subsets in the EAM hearts (Figure 6E, H). 
However, the heart infiltrating CD45.1+ monocytes in the non-EAM CD45.2 mice can only 
differentiate into MHCII+ macrophages (Figure 6E, H). Taken together, our data supports 
the idea that during cardiac inflammation, infiltrating monocytes readily differentiate into 
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macrophages and these monocyte-derived cells can replenish all three macrophage 
subpopulations.  
During cardiac inflammation, mature Ly6Chi monocytes arise from common monocyte 
progenitors (cMoPs) in the BM before trafficking to the heart [198]. We examined the 
mature monocyte population in the BM in response to cardiac inflammation (see gating 
strategy in Figure 7B). We found a substantial presence of CD45.1+ grafted cells in the 
CD45.2 parabiont BM, whereas CD45.2+ monocytes were relatively rare in the CD45.1 
EAM parabiont BM (Figure 7C, D). We speculated that this could be due to 
undifferentiated CD45.1+ Ly6Chi monocytes homing back to the CD45.1 BM in the 
absence of inflammation [170]. Alternatively, a systemic response to adjuvants used for 
EAM induction in CD45.1+ parabionts could increase monocyte infiltration into non-EAM 
parabiont BM. Another possible explanation is that EAM BM is saturated with 
inflammatory cells which prevented CD45.2+ monocytes from infiltrating CD45.1 BM. 
Nevertheless, the ratio of Ly6Chi to Ly6Clo monocytes was highly comparable between 
parabionts in the BM (Figure 7E). Collectively, the similarity of monocyte ratios in the BM 
between EAM and naïve mice suggests the local cardiac inflammatory milieu is 




Figure 6. Monocyte dynamics during myocarditis 
(A) Schematics of parabiosis mice. (B) Representative images of H&E-stained heart 
sections of the median animal from day 21 EAM induced CD45.1 mice and CD45.2 non-









CD45.2 non-EAM (Gated on single live  CD11b+Ly6G-Lineage- cells)

































































































































































counts between parabionts. (D) Comparison of total count of cardiac macrophages 
between parabionts. (E) Flow cytometry plots showing (Top left) Percentage of 
CD45.2+CD11b+Ly6G–Lineage (CD3e, B220, NKp46, CD90.2 and Ter119)– grafted cells 
infiltrating the CD45.1 EAM hearts; (Top middle) Percentage of grafted cells in the hearts 
that differentiated into macrophages or remained as monocytes; (Top right) Percentage 
of grafted cell derived macrophage subsets each defined by CCR2 and MHCII 
expressions. (Bottom left) Percentage of CD45.1+CD11b+Ly6G–Lineage– grafted cells 
infiltrating the CD45.2 non-EAM hearts; (Bottom middle) Percentage of grafted cells in 
the hearts that differentiated into macrophages or remained as monocytes; (Bottom right) 
Percentage of grafted cell derived macrophage subsets each defined by CCR2 and 
MHCII expressions. (F) Percentages of grafted monocyte-derive macrophages out of total 
grafted CD11b+Ly6G–Lineage– myeloid cells. (G) Percentages of grafted Ly6Chi and 
Ly6Clo cells out of total grafted F4/80–CD64+ monocytes. (H) Comparison of grafted MDM 
subsets defined by CCR2 and MHCII expressions between parabiotic mice. Data are 
representative of two independent experiments with biological triplicates. All data are 
presented as mean ± SD; n = 3. (C, D, F, G) Groups were compared using Student’s t 






Figure 7. Characterization of monocytes and/or macrophages in murine hearts and bone 
marrows during EAM development 
(A) Representative gating strategy showing identification of CD11b+Ly6G–Lin– myeloid 
cells in the hearts. (B) Representative gating strategy showing identification of mature 
Lin–CD11b+Ly6G–c-kit–Flt3– monocytes in the BM. (C) Flow cytometry plots showing 
grafted Lin–CD11b+Ly6G–c-kit–Flt3– monocytes that consist of both Ly6ChiCCR2+ and 
Ly6CloCCR2– populations in the bone marrow (BM). (D) Percentages of grafted Lin–
CD11b+Ly6G–c-kit–Flt3– monocytes in the BM. (E) Percentages of grafted Ly6Chi and 
Ly6Clo monocytes out of total grafted monocytes in the BM. (A) (B) Lineage includes 
CD3e, B220, NKp46, CD90.2 and Ter119. Data are representative of two independent 
experiments with biological triplicates. All data are presented as mean ± SD. Groups 
were compared using Student’s t test. ***, P < 0.001.  
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Cardiac fibroblasts facilitate Ly6Chi and Ly6Clo monocyte-to-macrophage differentiation  
The results from the parabiosis experiments suggested that MDMs in an inflamed cardiac 
environment are a highly heterogenous population. Whether macrophage heterogeneity 
is instigated by monocyte intrinsic differences and/or extrinsic environmental factors is 
not yet known. We and others have recently reported that cardiac fibroblasts play a key 
sentinel role in the myocardium. Cardiac fibroblasts produce myelotropic chemokines and 
cytokines such as GM-CSF and CCL2 in response to cardiac injury in myocarditis [247, 
442]. This immune modulatory property of cardiac fibroblasts was also confirmed in MI 
and Kawasaki disease [443, 444]. To examine whether Ly6Chi and Ly6Clo monocytes 
have the capacity to differentiate into macrophages and whether cardiac fibroblasts 
facilitate this differentiation process, we established an in vitro co-culture system. We 
harvested primary cardiac fibroblasts from naïve WT mice and co-cultured them with 
FACS-sorted IL-17Ra–/– EAM splenic Ly6Chi or Ly6Clo monocytes for up to 160 hours 
(Figure 8A; see gating strategy in Figure 9A). Due to the relative paucity of monocytes in 
blood, we used spleen as a surrogate source of monocytes. Using flow cytometry, we 
found that approximately 80% of the Ly6Chi monocytes quickly differentiated to become 
macrophages, while almost all Ly6Clo monocytes remained undifferentiated over the first 
40 hours of culture (Figure 8B, C). However, when we assessed their phenotypic changes 
at 160 hours, approximately 30% of the Ly6Clo monocytes had become macrophages 
(Figure 8D, E). Neither Ly6Chi nor Ly6Clo monocytes were able to survival long-term nor 
differentiate into macrophages in the absence of cardiac fibroblasts (Figure 8D, E). Ly6Chi 
and Ly6Clo MDMs were morphologically similar and resembled macrophages after 160 
hours of co-culture with cardiac fibroblasts (Figure 8F). To better understand how 
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monocytes and cardiac fibroblasts interact in vitro, we used live-cell time-lapsed imaging 
to track CFSE-labeled (CFSE+) Ly6Chi and Ly6Clo monocytes co-cultured with CFSE– 
cardiac fibroblasts. We found that CFSE+Ly6Chi monocytes started to cluster around 
cardiac fibroblasts as early as 9 hours into co-culture. They adhered strongly to the 
cardiac fibroblasts and became static when adhesions formed (Figure 8G). In contrast, 
CFSE+Ly6Clo monocytes were motile and they formed transient clusters around cardiac 
fibroblasts. Ly6Clo monocytes also lose CFSE at a higher rate, indicating faster 
proliferation when compared to Ly6Chi monocytes (Figure 8H). Flow cytometric analysis 
confirmed that Ly6Clo monocytes indeed proliferate faster than Ly6Chi monocytes (Figure 
9B, C). Next, we used transmission electron microscopy (EM) to examine whether MDMs 
and cardiac fibroblasts establish cell-to-cell connections, which would suggest the 
presence of molecular adhesion structures. We observed that the cytoplasm of both 
Ly6Chi and Ly6Clo MDMs contained a large number of electron-lucent vesicles (Figure 8I, 
J). Each subset of MDMs formed close cell-to-cell contact with cardiac fibroblasts (Figure 
8K, L). Interestingly, these close cell-to-cell interactions are important for driving 
monocyte to macrophage differentiation. We demonstrated a significant reduction in 
monocyte-to-macrophage differentiation when monocyte-fibroblast contacts are inhibited 
by a transwell barrier (Figure 9D, E). We also showed that Ly6Chi monocytes induced 
cardiac fibroblasts to significantly upregulate Ccl2 mRNA levels compared to Ly6Clo 
monocytes, ensuring a feed-forward loop for a continuous supply of pro-inflammatory 
monocytes to accumulate in an inflamed microenvironment (Figure 9F). Taken together, 
Ly6Chi and Ly6Clo monocytes establish close physical contact with cardiac fibroblasts and 
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these cell-to-cell interactions play a role in facilitating Ly6Chi and Ly6Clo monocytes 




Figure 8. Direct contact with cardiac fibroblasts facilitate Ly6Chi and Ly6Clo monocyte-to-
macrophage differentiation 
(A) Schematics of the monocytes and cardiac fibroblasts co-culture system. Cardiac 
fibroblasts were harvested from WT naïve mice, whereas monocytes were sorted from 
EAM IL-17Ra–/– mice. (B) Flow cytometric analysis showing differentiation of viable Ly6Chi 
and Ly6Clo monocytes to become F4/80hiCD64+ cells at 40 hours via flow cytometry. (C) 
Quantification of the frequency of macrophage differentiation at 40 hours. (D) 
Differentiation of viable Ly6Chi and Ly6Clo monocyte derived cells were assayed at 160 
hours via flow cytometry. (E) Quantification of the frequency of macrophage differentiation 
at 160 hours. (F) Giemsa staining of monocytes morphologies before culture and after 
160 hours co-culture with cardiac fibroblasts. Bars: (black) 8 µm (G) IncuCyte Imaging 
showing CFSE+Ly6Chi and (H) CFSE+Ly6Clo monocytes are in close contact when 
interacting with cardiac fibroblasts. Bars: (white) 50 µm. Representative images of EM 
images showing (I) Ly6Chi and (J) Ly6Clo MDMs, and (K) Ly6Chi and (L) Ly6Clo MDMs 
are in close contacts with cardiac fibroblasts. Images taken at 160 hours of co-culture. 
Bars: (white) 2 µm; (black) 2 µm. (A – F) Data are representative of five independent 
experiments with technical triplicates. (C, E) Data are presented as mean ± SD; n = 3. 
Groups were compared using one-way ANOVA followed by Tukey test. ****, P < 0.0001. 





Figure 9. In vitro co-culture of splenic Ly6Chi or Ly6Clo monocytes with cardiac fibroblasts  
(A) Representative gating strategies of FACS sorted Ly6Chi and Ly6Clo monocytes from 
WT (or IL-17Ra–/–) EAM spleens. These monocytes were used for all adoptive transfers 
and in vitro co-culture experiments. Cells were gated stringently to obtain pure 
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populations. Lineage marks include CD3e, CD19, NKp46, CD49b. (B) Histograms of MFI 
showing CFSE staining of viable Ly6Chi and Ly6Clo monocytes at 40 hours and (C) at 160 
hours. (D) A transwell co-culture was established with cardiac fibroblasts in the lower 
chamber and either Ly6Chi or Ly6Clo monocytes on the upper chamber. Cells were 
separated with a 0.4-micron pore size membrane. We examined Ly6Chi and (E) Ly6Clo 
monocyte-to-macrophage differentiation at 40 hours and 160 hours respectively. (F) 
Separately, cardiac fibroblasts were harvested in 40 hours and Ccl2 mRNA levels were 
assessed. (D – F) Data are presented as mean ± SD. Data are representative of two 
independent experiments with technical triplicates. (C, D) Groups were compared using 
Student’s t test. **, P < 0.01. (E) Groups were compared using one-way ANOVA followed 




Inflammatory monocytes are the main precursors for monocyte-derived macrophages 
during myocarditis in both mice and humans  
Given that cardiac fibroblasts facilitate the differentiation of both Ly6Chi and Ly6Clo 
monocytes into macrophages, we next sought to investigate whether both Ly6Chi and 
Ly6Clo monocytes could differentiate in vivo during EAM development. We FACS-sorted 
splenic CD45.2+ Ly6Chi or Ly6Clo monocytes from WT mice on day 14 of EAM, and 
intracardially injected them into CD45.1 WT recipients at the peak of EAM (Figure 10A). 
Both Ly6Chi and Ly6Clo monocytes and monocyte-derived cells of donor origin persisted 
in the myocardium 40 hours after the injection (Figure 10B, C). Approximately 50% of the 
injected Ly6Chi monocytes had differentiated into F4/80hiCD64+ macrophages (Figure 
10D, C), whereas less than 1% of the Ly6Clo monocytes differentiated into macrophages 
(Figure 10D, F). We employed Barnes-Hut Stochastic Neighbor Embedding (bh-SNE) 
analysis to visualize monocyte to macrophage differentiation [445, 446]. We confirmed 
that CD45.2+ Ly6Clo monocytes were mostly unable to differentiate into F4/80hiCD64+ 
macrophages, while CD45.2+ Ly6Chi monocytes contributed significantly to the cardiac 
macrophage pool during EAM (Figure 10G, H). We also examined Ly6Chi and Ly6Clo 
monocytes differentiation at 160 hours in vivo, and found that very few injected monocytes 
were present in the myocardium, indicating a high local turn-over rate. Notably, we did 
not find evidence suggesting Ly6Clo monocyte-to-macrophage differentiation (data not 
shown). Upon immunofluorescence examination of endomyocardial biopsy samples from 
a patient with giant cell myocarditis, we found the expression of CD68, a pan macrophage 
marker, coincided with CD14 but not CD16. This suggest that the inflammatory 
CD14+CD16–/+ but not the patrolling CD14–CD16+ monocyte populations are the likely 
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source of macrophages in giant cell myocarditis (Figure 11A, B). In parallel, we examined 
endomyocardial biopsies from three patients who had left ventricular assist devices 
implanted as a result of heart failure with various etiologies (Table 5). Flow cytometric 
analysis from all three patients indicated that CD14+CD68+, but not CD16+CD68+ 
macrophages are present in the heart (Figure 11C). Further supporting the hypothesis 
that CD14+CD16- monocytes are the main source of cardiac macrophages in human 
myocarditis. In conclusion, human CD14+ and mouse Ly6Chi monocyte subsets are the 
major contributors to the cardiac macrophage population during myocarditis development.  
 
 
Figure 10. Inflammatory monocytes are the main precursors for monocyte-derived 



















































































(A) Schematics of intracardiac injection of Ly6Chi or Ly6Clo CD45.2+ splenic monocytes 
into the heart of a CD45.1 day 21 EAM WT recipient mice. (B) Gating of concatenated 
Ly6Chi and (C) Ly6Clo donor cells from total viable CD115+CD11b+ population. (D) 
Quantification of the percentages of injected Ly6Chi or Ly6Clo monocytes differentiated 
into macrophages. (E) Flow cytometric analysis of the frequencies of Ly6Chi MDMs and 
(F) Ly6Clo MDMs out of viable CD45.2+CD115+CD11b+ population. F4/80 and CD64 
expression intensities of (G) Ly6Chi MDMs and (H) Ly6Clo MDMs using bh-SNE 
dimensional reduction algorithm. (D) Data are presented as mean ± SD; n = 3 – 4. 
Groups were compared using Student’s t test. **, P <0.01. Data are representative of 
three independent experiments. See also Figure 11, Table 5. 
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Figure 11. Examination of human macrophage ontogeny 
(A) Immunofluorescent (IF) staining of CD14 (red) and CD68 (green) in a human giant 
cell myocarditis biopsy sample showing numerous CD14+CD68+ double positive cells 
(blue arrows) and some CD14+CD68– single positive cells (yellow arrows). (B) 
Immunofluorescent (IF) staining of CD16 (red) and CD68 (green) in a human giant cell 
myocarditis biopsy sample showing numerous CD16–CD68+ single positive cells (green 
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arrows) and few CD16+CD68– single positive cells (red arrows). (C) Gating of CD16+ or 
CD14+ and CD68+ from viable CD45+CD11b+ myeloid cells in the hearts of three patients 
with ventricular assist device explant. 
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Age 32 61 57 
Race/Ethnicity Caucasian Caucasian Caucasian 
Gender Male Male Male 
Etiology Viral myocarditis Ischemic Ischemic 
Type of VAD HM II 10600 3000 rpm 8000 rpm 
Diabetes No No Yes 
Height 175 cm 170 cm 180 cm 
Weight 86.63 Kg 86.63 Kg 100.69 Kg 
LVIDd 3.9 cm 6.6 cm 6.5 cm 
LVPWd 1.3 cm 0.9 cm 1.0 cm 
IVSd 1.6 cm 1.1 cm 1.0 cm 
EF       
Troponin level   <0.15   
Days on VAD 1167 270 432 
Explant reason OHT OHT OHT 
Dead No No No 
BNP   185 376 
CKMB   1.7 0.5 
Tissue Amount (mg) 307.5 (LV) 294.1 (LV) 339.6 (LV) 
Path explant   
cardiomegaly, 
concentric LVH, 
posterior wall fibrosis, 
fatty infiltration of IVS, 








Table 5. Patient information part I. 
Patient information from individuals presenting with end stage heart failure who 
underwent implantation of a Left Ventricular Assist Device at the Texas Heart Institute. 
Tissues were collected for flow cytometry assessments. Gray Fill: Data Not available; 





IL-17A signaling through cardiac fibroblasts inhibits Ly6Clo monocyte-to-macrophage 
differentiation and Ly6Clo proliferation  
Given the differentiation capacity of Ly6Clo monocytes shown above in vitro, we next 
sought to understand what factors limit their differentiation in vivo. EAM is a Th17 driven 
disease and IL-17A induces production of myelotropic cytokines and chemokines by 
cardiac stroma cells [247]. We speculated that IL-17A might play a role in determining 
monocyte fate during EAM. Since monocytes require cardiac fibroblasts to differentiate 
into macrophages, we co-cultured FACS-sorted IL-17Ra–/– EAM Ly6Chi and Ly6Clo 
splenic monocytes with either cardiac fibroblasts alone or IL-17A stimulated cardiac 
fibroblasts for 160 hours. We found that IL-17A stimulated cardiac fibroblasts significantly 
inhibited Ly6Clo monocyte-to-macrophage differentiation, while its effect on Ly6Chi 
monocyte differentiation was minimal (Figure 12A). Using CFSE labeling, we found that 
proliferation of Ly6Clo monocytes was almost completely inhibited by cardiac fibroblasts 
stimulated with IL-17A, whereas proliferation of Ly6Chi monocytes was minimally affected 
(Figure 12B). We described previously that cardiac fibroblasts are potent producers of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) upon IL-17A stimulation 
[247]. We found that while treatment with recombinant GM-CSF only marginally 
suppressed Ly6Chi monocyte-to-macrophage differentiation (Figure 12C), it completely 
recapitulated the inhibitory effect of IL-17A through cardiac fibroblasts on Ly6Clo 
monocyte-to-macrophage differentiation (Figure 12D). IL-17A-induced inhibition of Ly6Clo 
monocyte-to-macrophage differentiation could be reversed with anti-GM-CSF treatment 
(Figure 12D). Similarly, GM-CSF did not change proliferation of Ly6Chi monocytes and 
MDMs, while completely inhibiting proliferation of undifferentiated Ly6C lo monocytes 
(Figure 12E, F). Treatment of anti-GM-CSF to IL-17A-stimulated cardiac fibroblasts 
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restored proliferation of Ly6Clo monocytes (Figure 12F). We further validated all of our 
major in vitro findings using splenic monocytes from WT animals and showed that 
monocytes responded to environmental cues similarly regardless of their sources (Error! 
Reference source not found.). To summarize, GM-CSF acts as a downstream mediator 
of IL-17A signaling through cardiac fibroblasts that exhibits minor inhibitory effects on 
Ly6Chi monocyte differentiation and proliferation, but substantially inhibits Ly6C lo 




Figure 12. IL-17A signaling through cardiac fibroblasts inhibits Ly6Clo monocyte-to-
macrophage differentiation and Ly6Clo monocyte proliferation 
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All co-cultured cells were assessed using flow cytometry at 160 hours. (A) Gating of 
concatenated Ly6Chi and Ly6Clo monocyte-derived macrophages out of viable 
CD45+CD11b+. (B) Histograms of mean fluorescent intensity (MFI) showing CFSE 
staining of the viable Ly6Chi cells and Ly6Clo cells after co-culturing with either cardiac 
fibroblasts or IL-17A treated cardiac fibroblasts. (C) Percentages of macrophages derived 
from Ly6Chi monocytes (D) and Ly6Clo monocytes with cardiac fibroblasts only, IL-17A 
stimulated cardiac fibroblasts, recombinant GM-CSF supplemented cardiac fibroblasts 
and IL-17A stimulated cardiac fibroblasts treated with anti-GM-CSF, respectively. (E) 
Histograms of MFI showing CFSE staining of the viable Ly6Chi monocyte-derived 
macrophages and (F) Ly6Clo monocytes with cardiac fibroblasts only, IL-17A stimulated 
cardiac fibroblasts, recombinant GM-CSF supplemented cardiac fibroblasts and IL-17A 
stimulated cardiac fibroblasts treated with anti-GM-CSF, respectively. (C, D) Data are 
presented as mean ± SD. Data are representative of three independent experiments with 
technical triplicates. (C – D) Groups were compared using one-way ANOVA followed by 






Figure 13. Validation of WT monocyte differentiation in vitro  
Cardiac fibroblasts were harvested from WT naïve mice, whereas monocytes were sorted 
from either EAM WT or EAM IL-17Ra–/– mice. (A) Flow cytometry plots showing 
differentiation status of splenic Ly6Chi monocyte from either WT or IL-17Ra–/– mice. (B) 
Quantification of the percentages of macrophages derived from Ly6Chi monocytes in 
culture. (C) Flow cytometry plots showing differentiation status of splenic Ly6Clo monocyte 
from either WT or IL-17Ra–/– mice. (D) Quantification of the percentages of macrophages 
derived from Ly6Clo monocytes in culture. (E) Flow cytometry plots showing the inhibitory 
effects of IL-17A and GM-CSF on Ly6Clo monocyte-to-macrophage differentiation, 
regardless of monocyte source. Cardiac fibroblasts supernatant alone cannot promote 
WT and IL-17Ra–/–Ly6Clo monocyte-to-macrophage differentiation. (F) Quantification of 
the percentages of macrophages derived from Ly6Clo monocytes in culture. 
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The absence of IL-17A signaling enables Ly6Clo monocyte-to-macrophage differentiation 
in vivo 
We next aimed to test in vivo whether eliminating IL-17A signaling during EAM would 
enable Ly6Clo monocytes to undergo differentiation. To begin, we intracardially injected 
either FACS-sorted CD45.2+Ly6Chi or Ly6Clo monocytes into CD45.1 IL17Ra–/– recipients 
during the peak of EAM (Figure 14A). Both monocyte subsets were present in the 
myocardium after 40 hours post injection (Figure 14B, C). Strikingly, while most of the 
Ly6Chi monocytes differentiated into F4/80hiCD64+ macrophages, approximately 30% of 
the Ly6Clo monocytes also differentiated into macrophages (Figure 14D – F). The bh-
SNE algorithm further confirmed that while Ly6Chi monocytes contributed in substantial 
numbers to the cardiac macrophage pool, a non-negligible proportion of Ly6Clo 
monocytes had also differentiated into F4/80hiCD64+ macrophages (Figure 14G, H). In 
addition, we examined whether the Ly6Clo monocytes are able to traffic through blood 
and differentiate in the myocardium. We retro-orbitally injected FACS sorted 
CD45.1+Ly6Clo monocytes into either CD45.2 WT or IL17Ra–/– recipients during the peak 
of EAM (Figure 14I).  CD45.1+Ly6Clo monocytes could be found in the myocardium after 
40 hours post injection (Figure 14J, K). Consistent to our finding, approximately 30% of 
the Ly6Clo monocytes had differentiated into F4/80hiCD64+ macrophages in IL17Ra–/– 
recipients but not in WT (Figure 14L – N). Therefore, our results indicate that the absence 
of IL-17A signaling enables Ly6Clo monocyte-to-macrophage differentiation. Again, 



















































































































































Figure 14. Ly6Clo monocyte-to-macrophage differentiation can be initiated in vivo in the 
absence of IL-17A signaling through cardiac fibroblasts 
(A) Schematics of intracardiac injection of Ly6Chi or Ly6Clo CD45.2 monocytes into 
CD45.1 day 21 EAM IL-17Ra–/– recipient mice. (B) Gating of concatenated Ly6Chi and (C) 
Ly6Clo donor cells from total viable CD115+CD11b+ population. (D) Percentages of 
injected Ly6Chi or Ly6Clo monocytes differentiated into macrophages. (E) Frequencies of 
Ly6Chi monocyte-derived macrophages and (F) Ly6Clo monocyte-derived macrophages 
out of viable CD45.2+CD115+CD11b+ population. F4/80 and CD64 expression intensities 
of (G) Ly6Chi monocyte-derived and (H) Ly6Clo monocyte-derived macrophages using bh-
SNE dimensional reduction algorithm. (D) Groups were compared using Student’s t test. 
**, P < 0.01. Data are representative of two independent experiments with biological 
triplicates.  
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Distinct gene expression profiles in Ly6Chi and Ly6Clo monocyte-derived macrophage 
subsets in vitro 
To explore the molecular differences between these MDM subpopulations, we next 
characterized the changes in gene expression that occurred during Ly6C lo and Ly6Chi 
monocyte-to-macrophage differentiation after being co-cultured with cardiac fibroblasts 
(condition 1 and 2). In addition, we also examined the effect of IL-17A stimulated cardiac 
fibroblasts on Ly6Chi MDMs (condition 3). Since there were very few Ly6Clo MDMs in the 
co-culture with IL-17A stimulated cardiac fibroblasts, this condition was not included for 
this analysis. We performed microarray-based transcriptomic profiling of RNA isolated 
from FACS sorted macrophages derived from the three conditions in triplicate (see gating 
strategy in Figure 15A). Gene expression profiles of the three MDM subsets were 
evaluated by principal component analysis (PCA) and hierarchical clustering analysis 
(Figure 16A, B). Both analyses demonstrated distinct gene expression profiles for the 
three MDM subsets, suggesting that both the microenvironment and monocyte intrinsic 
properties are determining factors. Differential gene expression analysis showed that 
consistent with both PCA and hierarchical clustering analysis, Ly6C lo MDMs versus 
Ly6Chi MDMs from IL-17A treated cardiac fibroblast culture had the greatest number of 
differentially expressed genes (n = 1057). Whereas Ly6Clo MDMs versus Ly6Chi MDMs 
from non-treated cardiac fibroblasts culture had the lowest number of differentially 
expressed genes (n = 644) (Figure 15B). We found that IL-17A signaling through cardiac 
fibroblasts significantly up-regulated genes encoding inflammatory chemokines, 
cytokines, growth factors, Il6/Stat3 and the NFB pathway in Ly6Chi MDMs (Figure 16C 
– E). Moreover, IL-17A trans-signaling through cardiac fibroblasts up-regulated genes in 
Ly6Chi MDMs known to promote tissue fibrosis such as Osm, as well as genes related to 
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extracellular matrix degradation including Mmp9 and Timp1 (Figure 16F). In contrast, 
Ly6Clo MDMs uniquely upregulated genes associated with class II antigen processing, 
including Cd74, H2-Ab1 (Figure 16D). Flow cytometric analysis showed that in vitro 
Ly6Clo MDMs indeed express MHCII, strongly suggesting their antigen presenting 
capabilities (Figure 16G). Ly6Clo MDMs also express significantly more MHCII than 
Ly6Chi MDMs when injected intracardially into EAM IL17Ra–/– recipients (Figure 15C). 
Furthermore, MHCII+Ly6Clo MDMs contribute to the increased proportion of MHCII+ 
macrophage in IL17Ra–/– mice during the resolution phase of EAM at day 28 (Figure 16H). 
We also validated that Ly6Clo MDMs do not carry a dendritic cell signature (Figure 15D). 
IL-17A signaling through cardiac fibroblasts significantly up-regulated many genes 
encoding both M1 and M2 markers in the Ly6Chi MDMs, highlighting that the classic 
M1/M2 paradigm cannot simply characterize macrophages activation complexity during 
disease states (Figure 15E) [447, 448]. We conclude that IL-17A trans-signaling through 
cardiac fibroblasts promotes pro-inflammatory and pro-tissue remodeling characteristics 
in Ly6Chi MDMs. Interestingly, Ly6Clo MDMs upregulate genes associated with antigen 
presentation and have elevated surface expression of MHCII both in vitro and in vivo. Our 
findings suggest that Ly6Chi and Ly6Clo MDMs represent distinct subsets that have 






Figure 15. Validating the identities of in vitro derived macrophage subsets  
(A) Representative gating strategy used to FACS sort CD45+CD11b+CD64+F4/80hi 
macrophages from the heart for in vitro monocyte-fibroblast co-culture. F4/80 isotype 
control RatIgG2a was included. (B) Bar graph displaying the number of differentially 
regulated genes, using a threshold of 2  fold change and p value<0.05. (C) Frequencies 
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of MHCII+ subset out of total intracardially injected MDMs in IL-17Ra–/– recipient mice 
were assessed by flow cytometry. (D) Heat maps showing relative fold changes in genes 
associated with dendritic cells and (E) M1/M2 dichotomy of macrophages. (C) Data are 
presented as mean ±  SD, and representative of two independent experiments with 
biological triplicates. Groups were compared using Student’s t test. *, P < 0.05. (D) * 
Represent selected genes displayed on the heat maps have a one-way ANOVA p 
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Figure 16. Distinct gene expression profiles in Ly6Chi and Ly6Clo monocyte-derived 
macrophage subsets differentiated in vitro in the presence of untreated or IL-17A-treated 
cardiac fibroblasts 
(A) PCA analysis of microarray experiments. The principal components and their fraction 
of overall variability of the data (%) are shown on the x-axis, the y-axis and the z-axis. (B) 
Supervised hierarchical clustering highlighting differential gene expression profiles 
among three groups of in vitro MDMs, using a threshold of 2-fold change and p-value < 
0.05. Sample number scheme is identical to the legend in all heat maps below. (C) Heat 
maps showing relative fold changes in genes associated with cytokines and growth 
factors, (D) NFB pathway and antigen presentation, (E) chemokines and immune 
modulating activities and (F) collagen production and matrix remodeling. (G) Gating of 
MHCII+CD64+ macrophages derived from monocyte-fibroblast co-culture. Frequencies of 
MHCII+ subset out of total in vitro co-culture derived macrophages were assessed by flow 
cytometry. (H) Hearts from day 28 EAM mice. Frequencies of MHCII+ out of F4/80hiCD64+ 
macrophages were assessed by flow cytometry. (B – F) All genes displayed on the heat 
maps have one-way ANOVA p value < 0.05 among groups compared. (G) Data are 
presented as mean ± SD; n = 3. (H) Data are presented as mean ± SD; n = 8 – 9. (G) 
Data are representative of three independent experiments with technical triplicates. 
Groups were compared using one-way ANOVA followed by Dunnett test. **, P < 0.01. (H) 
Groups were compared using Student’s t test. **, P < 0.01. See also Figure 15. 
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IL-17A trans-signaling through cardiac fibroblasts down-regulates MerTK expression on 
monocytes and monocyte-derived macrophages  
The clearance of apoptotic cells during inflammation resolution is critical for proper wound 
repair and tissue remodeling. The myeloid-epithelial-reproductive receptor tyrosine 
kinase (MerTK) is a major apoptotic cell receptor on macrophages, known to play a role 
in the clearance of dying cells, a process called efferocytosis [449, 450]. Efferocytosis is 
also known to induce an anti-inflammatory phenotype in macrophages and diminish 
proinflammatory cytokine release [451-453]. EM results showed engulfed apoptotic cells 
or large cell debris inside Ly6Chi MDMs (Figure 17A, B). Their phagocytic index was 
significantly elevated compared to the Ly6Clo MDMs derived from the co-culture (Figure 
17C). This indicates that Ly6Chi MDMs are professional phagocytes. Consistent with our 
finding that IL-17A modulates the replenishment of the tissue macrophage pool with 
circulating monocytes, we observed an increase in the percentage of F4/80hiCD64+ 
macrophages in IL-17Ra–/– EAM hearts compared to WT EAM hearts (Figure 17D; see 
gating strategy in Figure 18A). In general, macrophages express considerably higher 
levels of MerTK than monocytes in the hearts (Figure 18B). We found higher MerTK 
expression levels in both the macrophage and monocyte compartments from IL17Ra–/– 
hearts compared to WT (Figure 17E, F). This suggests that IL-17A plays a role in down-
regulating MerTK expression on monocytes and macrophages. Furthermore, we found 
significantly less soluble Mer (sMer) present in IL17Ra–/– mice sera than WT animals, 
indicating that IL-17A might influence the rate at which MerTK is proteolytically cleaved 
from the surface of the cell (Figure 17G). In order to confirm that IL-17A signaling through 
cardiac fibroblasts was responsible for modulation of MerTK, we assessed MerTK 
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expression in vitro. We confirmed that in vitro MerTK was predominantly expressed by 
Ly6Chi but not Ly6Clo monocytes and MDMs (Figure 17H). Moreover, IL-17A signaling 
through cardiac fibroblasts resulted in a significant down-regulation of MerTK expression 
on Ly6Chi monocytes and MDMs (Figure 17H). In addition, we observed that sMer was 
significantly elevated in the co-culture supernatants when IL-17A signaling was present 
(Figure 17I). Our findings suggest that IL-17A stimulated cardiac fibroblasts can suppress 
macrophages’ phagocytic function by promoting MerTK cleavage resulting in reduced 
surface MerTK expression. Our results also suggest that Ly6Chi MDMs in WT EAM hearts 
have compromised phagocytic activities during heart inflammation. We retro-orbitally 
injected FITC conjugated latex beads in both IL17Ra–/– and WT EAM mice. We found 
significantly more FITC+ macrophages in the hearts of IL17Ra–/– compared to WT, 
indicating enhanced phagocytic activity in an IL-17A signaling deficient environment 
(Figure 17J, K). Human myocarditis patients were reported to have high serum IL-17A, 
as well as an abundant presence of Th17 cells in their hearts and blood [454]. Indeed, we 
found higher frequencies of IL-17A expressing infiltrating leukocytes in the hearts of 
myocarditis patients compared to patients with ischemic cardiomyopathy (Figure 18C, D; 
Table 6 and Table 7). We therefore hypothesized that myocarditis patients could have 
lower MerTK expression in their cardiac myeloid population. In a cohort of heart failure 
patients, we found a significant reduction in myeloid MerTK expression in patients with 
myocarditis as compared to those with ischemic heart failure, similar to our finding in 
murine model (Figure 17L; Table 6 and Table 7). In conclusion, IL-17A signals through 
cardiac fibroblasts to promote MerTK cleavage on Ly6Chi MDMs, thus compromising the 
processes of efferocytosis. With reduced phagocytic ability as a result of surface MerTK 
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modulation, we predict that macrophages are less efficient in clearing apoptotic cells 
efficiently and more likely to exhibit a proinflammatory phenotype, which in turn could 
promote irreversible cardiac remodeling and fibrosis.  
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Figure 17. IL-17A signaling through cardiac fibroblasts downregulates MerTK expression 
on monocytes and monocyte-derived macrophages 
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(A) Representative images of EM showing apoptotic cells or apoptotic cellular debris 
internalized by Ly6Chi MDMs (arrowheads) and (B) engulfed cellular debris were largely 
absent in Ly6Clo MDMs. Bars: (black) 2 µm. (C) Macrophage phagocytic index was 
calculated using the following formula: (Number of engulfed apoptotic cells/Total number 
of macrophages)  (Number of macrophages with engulfed apoptotic cells/Total number 
of macrophages)  100. (D – G) Hearts from day 21 EAM mice. (D) Frequencies of 
F4/80hiCD64+ macrophages out of viable CD45+Ly6G–CD11b+ cells were assessed by 
flow cytometry. (E) MerTK MFI of F4/80hiCD64+ macrophages in the hearts. (F) MerTK 
MFI of F4/80–CD64+ monocytes in the hearts. (G) Concentration of soluble Mer (sMer) 
detected in WT and IL-17Ra–/– EAM mice sera using an ELISA. (H – I) Cardiac fibroblasts 
were harvested from WT naïve mice, whereas monocytes were sorted from EAM IL-
17Ra–/– mice. (H) MFI of MerTK expression of Ly6Chi or Ly6Clo monocytes and MDMs in 
vitro after 160 hours post-co-culture with cardiac fibroblasts stimulated with or without IL-
17A. (I) sMer detected in supernatants of the monocyte-fibroblast co-culture by ELISA. 
(J) Flow cytometric analysis of the frequencies of FITC+F4/80hiCD64+ macrophages in the 
myocardium of WT, IL-17Ra–/– and non-treated controls. (K) Quantification of the 
percentages of FITC+F4/80hiCD64+ macrophages out of viable CD45+Ly6G–CD11b+ cells. 
(L) MerTK MFI in patients with either myocarditis or ischemic cardiomyopathy. (D – G) 
Data are representative of five independent experiments. Results are presented as mean 
± SD; n = 8 – 9. (H – I) Data are representative of three independent experiments with 
technical triplicates. Results are presented as mean ±  SD; n = 3. (J, K) Data are 
representative of two independent experiments. Results are presented as mean ± SD; n 
= 3. (C – G, I, K, L) Groups were compared using Student’s t test. *, P < 0.05 **, P < 0.01. 
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(H) Groups were compared using one-way ANOVA followed by Dunnett test. **, P < 0.01 
****, P < 0.0001. See also Figure 18, Table 6 and 7. 
 
Figure 18. Murine MerTK expression levels by monocytes and macrophages and IL-17A 
levels in human endomyocardial biopsies 
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(A) Flow cytometry gating of concatenated CD45+Ly6G–CD11b+F4/80hiCD64+ 
macrophages and CD45+Ly6G–CD11b+F4/80–CD64+ monocytes in the hearts. 
Appropriate F4/80 isotype control was shown. (B) Macrophages and monocytes’ MerTK 
expression level as compared to isotype control for MerTK. (C) Representative 
immunohistochemistry staining for human IL-17A in heart tissue implant samples of 











Age 43 25 15 63 
Race/Ethnicity  Hispanic African American Caucasian 
Gender Male Male Male Male 
Etiology Viral Viral Viral Viral 
Type of VAD HM XVE HM II HM II Jarvik 2 
Diabetes No No No Yes 
Height 188 cm 172 cm 185 cm 183 cm 
Weight 100.01 Kg 100.69 Kg 113.39 Kg 87.54 Kg 
LVIDd  7.0 cm 7.2 cm 6.7 cm 
LVPWd  1.1 cm 0.8 cm 0.7 cm 
IVSd  1.1 cm 0.9 cm 0.7 cm 
EF 10 – 15% <20% <15% <15% 
Troponin level  <0.15     
Days on VAD 50 502 1121 600 
Explant reason OHT OHT To Jarvik, died 2d after  OHT 
Dead Yes No Yes No 
BNP  423 1163   
CKMB  0.2   2.2 
Tissue Amount 
(mg) 44 130 231.4 245.5 










Table 6. Patient information part II 
Viral myocarditis patient information from individuals presenting with end stage heart 
failure who underwent Left Ventricular Assist Device explant and orthotopic heart 
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transplant at the Texas Heart Institute. Tissues were collected for IHC and flow cytometry 






hy patient I 
Ischemic 
cardiomyopat
hy patient II 
Ischemic 
cardiomyopat
hy patient III 
Ischemic 
cardiomyopat
hy patient IV 
Ischemic 
cardiomyopat
hy patient V 
Age 61 59 64 56 72 
Race/Ethnici
ty Caucasian Caucasian Hispanic Caucasian Caucasian 
Gender Male Male Male Male Male 
Etiology Ischemic Ischemic Ischemic Ischemic Ischemic 
Type of VAD HM II HW HM II HM II HW 
Diabetes No No Yes Yes Yes 
Height 170 cm 170 cm 170 cm 180 cm 178 cm 
Weight 77.11 Kg 73.48 Kg 90.71 Kg 97.97 Kg 69.39 Kg 
LVIDd 6.92 cm 7.2 cm 7.0 cm 8.0 cm 6.9 cm 
LVPWd 1.1 cm 1.1 cm 1.0 cm 1.1 cm 1.0 cm 
IVSd 0.63 cm 0.9 cm 1.1 cm 1.0 cm 1.1 cm 
EF 20% 30% <15% 20% <20% 
Troponin 
level 0.06 <0.15 <0.15   <0.15 
Days on 
VAD 270 452 363 432 182 
Explant 
reason OHT OHT OHT OHT OHT 
Dead No No yes No No 
BNP 2983 222 1130 283 240 
CKMB 1.6 1.2 5.9   0.2 
Tissue 
Amount (mg) 273 251 240.6 271.9 218 
























Table 7. Patient information part III 
Ischemic cardiomyopathy patient information from individuals presenting with end stage 
heart failure who underwent Left Ventricular Assist Device explant and orthotopic heart 
transplant at the Texas Heart Institute. Tissues were collected for IHC and flow cytometry 





Monocytes and macrophages are key effector cells in the injured myocardium during 
human myocarditis and EAM [432, 433]. Although both Ly6Chi and Ly6Clo monocytes 
infiltrate the myocardium during EAM, we found that an excessive accumulation of Ly6Chi 
rather than Ly6Clo monocytes in the heart leads to adverse cardiac remodeling and the 
development of DCM [247]. However, it was unknown whether both infiltrating Ly6Chi and 
Ly6Clo monocytes contribute to the adverse cardiac tissue remodeling during 
development of EAM. Moreover, the role of the local pro-inflammatory cardiac 
microenvironment in influencing Ly6Chi and Ly6Clo monocyte fate and function was not 
well understood. We used three fate-mapping strategies to evaluate the phenotypic and 
functional changes of monocytes in the heart during myocarditis: parabiosis, adoptive 
transfer of monocytes, and an in vitro co-culture system.  
 
Under steady-state, adult cardiac tissue macrophages in mice are of mixed embryonic 
and hematopoietic origins [115-119]. In cases of aging or perturbed homeostasis, a 
greater proportion of embryonic derived macrophages are replaced by infiltrating 
monocytes, changing the landscape of macrophage dynamics in the heart. [119, 149, 
441]. Our parabiosis fate-mapping results reveal that monocytes extravasate into hearts 
during EAM and readily differentiate into macrophages, which contributes to the increase 
in cardiac macrophage number during EAM. It was previously reported that cardiac 
CCR2– macrophages including MHCII+ and MHCII– populations are largely embryonically-
derived, whereas cardiac CCR2+ macrophages represent a haematopoietically derived 
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lineage at steady-state [119, 455]. Embryonically derived macrophages are shown to 
have regenerative and reparative properties [455, 456], whereas CCR2+ macrophages 
are thought to initiate inflammation and contribute to adverse cardiac remodeling [457, 
458]. We report here that infiltrating monocytes predominantly contribute to the 
CCR2+MHCII+ macrophage compartment. Albeit to a lesser extent, they are also able to 
differentiate into CCR2–MHCII+ macrophages, with very few becoming CCR2–MHCII– 
macrophages in the chronically inflamed heart.  
 
Ly6Chi monocytes are known to replenish the macrophage pool during cardiac injury; 
however, the contribution of Ly6Clo monocytes to the cardiac macrophage pool has not 
been previously described [119, 171, 184, 245, 272, 439-441]. Here we show that both 
Ly6Chi and Ly6Clo monocytes have the capability to differentiate into macrophages, a 
process driven by direct contact with cardiac fibroblasts. Previously, we demonstrated 
that IL-17A can stimulate cardiac fibroblasts to produce significant amounts of GM-CSF 
[247]. Evidence from EAM, Kawasaki syndrome, and the mouse model of MI show that 
cardiac fibroblasts are potent producers of GM-CSF [247, 444, 459, 460]. An 
accumulating body of literature indicates that GM-CSF plays a key role in signaling 
myelopoiesis in response to tissue injury. GM-CSF also induces a pathogenic 
transcriptional signature in pro-inflammatory monocytes propelling the inflammatory 
cascade resulting in further tissue damage [247, 459, 461]. Here, we are the first to show 
a profound inhibitory role of IL-17A as it works in trans through cardiac fibroblast-derived 
GM-CSF on Ly6Clo monocyte-to-macrophage differentiation in vitro. We also confirmed 
in vivo the inhibitory effect of IL-17A signaling on Ly6Clo monocyte-to-macrophage 
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differentiation. We hypothesize that these Ly6Clo MDMs have distinct functions in 
myocarditis compared to Ly6Chi MDMs.  
 
Gene expression profiling results substantiate that Ly6Chi and Ly6Clo MDMs represent 
distinct cell types, possibly driven partly by intrinsic properties. Recent studies have 
demonstrated that Ly6Chi and Ly6Clo monocytes are phenotypically heterogenous 
populations. Intrinsic properties such as transcription factors regulate Ly6Chi and Ly6Clo 
monocyte fate and function during steady state or tissue injury [462-466]. However, we 
found that IL-17A signaling through cardiac fibroblasts accentuates a proinflammatory 
and pro-tissue remodeling gene profile in Ly6Chi MDMs. These macrophages up-regulate 
genes such as Il6, Mmp9, Timp1 and Osm, all of which have been implicated in cardiac 
dysfunction and maladaptive cardiac remodeling [467-472]. Unexpectedly, we found that 
Ly6Clo MDMs are enriched with genes associated with class II antigen processing. We 
confirm that Ly6Clo MDMs express higher levels of MHCII than their Ly6Chi counterparts 
in vitro. IL17Ra–/– mice develop EAM similar to their WT counterparts, but are protected 
from DCM, cardiac fibrosis and dysfunction [442]. In vivo, IL17Ra–/– EAM hearts contain 
more MHCII expressing macrophages than WT EAM controls during disease resolution, 
coinciding with DCM protection in IL17Ra–/– mice. The anti-inflammatory and 
proangiogenic properties of Ly6Clo monocytes were previously investigated, and their 
roles in the resolution of cardiac inflammation were frequently highlighted [171, 245, 247]. 
This suggests that MHCII+Ly6Clo MDMs might be beneficial in disease resolution and 
contribute to the protection of IL17Ra–/– mice from DCM and heart failure. The functions 
of Ly6Clo MDMs was placed under scrutiny recently. It has been implicated that they are 
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the precursors for wound healing macrophages in a soft tissue injury model [177]. 
Paradoxically, they were also shown to give rise to inflammatory macrophages in an 
autoimmune arthritis model [350]. We offer clues that Ly6Clo MDMs are a non-
inflammatory and non-tissue-remodeling population. The increased presence of these 
macrophages and an increased Ly6Clo to Ly6Chi ratio in EAM myocardium correlate with 
DCM protection in IL17Ra–/– mice [247]. Although phagocytic activity of Ly6Clo MDMs is 
unremarkable, their potential antigen presentation capability predicts their immune 
regulatory role in the heart. Whether MHCII+ Ly6Clo MDMs play a role in effector/memory 
T cell or regulatory T cell activation in the heart require further examination. Recent 
evidence indicated that MHCII+ macrophages loaded with cardiac myosin peptide are not 
effective in stimulating proliferation of autoreactive CD4+ T cell [473]. However, the 
beneficial effects of macrophages and regulatory T cells interactions during inflammation 
resolution and tissue regeneration have been reported [474, 475]. Currently, it remains 
unfeasible to selectively deplete Ly6Clo monocytes in mice. However, further experiments 
utilizing Nr4a1–/–, CX3CR1–/– or S1PR5–/– mice with reduced Ly6Clo monocytes can help 
to better assess specific functional role of Ly6Clo monocytes-derived macrophage in the 
context of myocarditis [218, 232, 476]. 
 
Macrophage function can be shaped by both progenitor origin and tissue 
microenvironment [113, 455]. We tested the hypothesis that upon IL-17A stimulation, 
cardiac fibroblasts play a role in modulating macrophage function. Recent data directly 
links the level of efferocytosis receptors on monocytes and macrophages to 
phagocytosis-dependent wound healing and restoration of organ function [477-480]. 
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Uncontrolled cellular necrosis and apoptosis during cardiac injury are integral 
components that contribute to adverse tissue healing and remodeling. Inefficient 
phagocytic clearance can also lead to exposure of self-antigens, which contribute further 
to autoimmune reactivity [481]. One of these efferocytosis receptors, MerTK, has been 
shown to be up-regulated on phagocytic cells during inflammation and plays an essential 
role in apoptotic cell recognition and clearance [449, 482-484]. Moreover, efferocytosis 
triggers a shift in macrophage activation making them phenotypically less 
proinflammatory [452, 453, 485]. Notably, our in vivo and in vitro results suggest that IL-
17A signaling through cardiac fibroblasts lead to MerTK shedding and the release of 
soluble Mer, which significantly reduces surface MerTK expression on Ly6Chi monocytes 
and MDMs. Cardiomyocytes have been shown to induce shedding of macrophage MerTK 
to suppress phagocytosis [486]. This highlights another mechanism by which IL-17A 
through cardiac fibroblasts can induce MerTK shedding, and in turn contributes to cardiac 
pathology in autoimmune myocarditis. Moreover, we showed that myeloid MerTK was 
significantly lower in human myocarditis patients when compared to ischemic patients. 
These findings warrant future studies to determine whether sMer can be used as a 
biomarker in clinical settings to differentiate patients with myocarditis from those with 
other types of cardiac diseases. 
 
Taken together, we underscore the fates of Ly6Chi and Ly6Clo monocyte subsets as a 
result of changes in the cardiac microenvironment. We demonstrate how the local cardiac 
milieu instructs cardiac fibroblasts to facilitate monocyte differentiation and proliferation 
as well as regulate the phenotype and function of monocytes and MDMs. Monocytes are 
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versatile immune cells playing a multi-faceted role in a wide range of inflammatory 
disorders [175, 177, 245, 296, 487, 488]. Our findings have broader implications for 
inflammatory diseases in the heart and other organs. We recently reported that IL-17A 
signaling to cardiac fibroblasts is associated with severe fibrosis and post-infarct death 
[444], which demonstrates a potential parallel concept that warrants future investigation. 
Ultimately, we anticipate that further studies of macrophage-cardiac fibroblast interactions 
will provide new insights into the development of targeted therapies that prevent 
deleterious inflammatory responses.   
 
Material and Methods 
Patients 
Endomyocardial biopsies from the apex of the left ventricle were obtained from patients 
with end stage heart failure (AHA stage D) of various etiologies. Biopsies were from 
patients who were undergoing either an implantation of Left Ventricular Assist Device 
(LVAD), or an orthotopic heart transplant after LVAD explant at the Texas Heart Institute. 
Details including patients’ age and gender are summarized in Table S1 – 3. Informed 
consent was obtained from human subjects and the study protocol was approved by the 
Committee for the Protection of Human Subjects (University of Texas Health Science 
Center at Houston. IRB #HSC-MS-05-0074). Samples were properly preserved in 
cryovials embedded in liquid nitrogen (-190oC) and then kept at -80oC in the tissue bank 
at the Texas Heart Institute, Houston, TX as previously described [489]. Aliquots of the 
samples were shipped frozen and processed in house. Reported diagnoses 
corresponded to clinical charts, based on standard histology (H&E), clinical presentation, 
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hemodynamic parameters, and routine clinical biochemical and serology parameters. 
Patient’s information of all samples was processed with random non-linked code 
relabeling in a database at the time of preservation. Furthermore, for each sample, a 
separate random non-linked code was assigned for the analyses process. Separately, 
one paraffin embedded, virus negative, acute giant cell myocarditis left ventricle 
transmural endomyocardial biopsy sample in Figure S3A and S3B were provided by Dr. 
Karin Klingel. The sample was taken for routine diagnostic purposes to identify infectious 
agents in the myocardium as described before [490]. Informed consent was obtained from 
human subjects and the study was approved by local ethic committee (Project-
No.253/2009BO2). Diagnosis of giant cell myocarditis was based on established criteria 
[18].  
Mice 
IL-17Ra–/– mice on BALB/c background were provided by Amgen Inc. (Thousand Oaks, 
CA) and Dr. J. Kolls (Children’s Hospital, University of Pittsburgh Medical Center, 
Pittsburgh, PA) [247, 491]. CByJ.SJL(B6)-Ptprca/J (CD45.1) mice (006584) and WT 
BALB/cJ (000651) mice were purchased from The Jackson Laboratory. IL-17Ra–/– mice 
were crossed to CByJ.SJL(B6)-Ptprca/J (CD45.1) mice and bred to homozygosity at both 
loci.  All mice were housed and maintained in the Johns Hopkins University School of 
Medicine specific pathogen-free vivarium. 6–10 weeks old healthy naïve male mice were 
randomly selected as the subjects of all of our studies. All experiments involving animals 
were in compliance with the Animal Welfare Act and strictly followed the Guide for the 
Care and Use of Laboratory Animals. The Animal Care and Use Committee of The Johns 
Hopkins University has approved all procedures and protocols used in this study.  
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Primary adult cardiac fibroblasts isolation and culture 
50U heparin was injected i.p. into 6 – 10-week-old male BALB/cJ naïve mice prior to 
sacrifice. Hearts were cannulated through the aorta and perfused for 3 minutes with 37°C 
perfusion buffer at 4 mL/minute: 7.03g/L NaCl, 1.1 g/L KCl, 0.082 g/L KH2PO4, 0.085 g/L 
Na2HPO4, 0.144 g/L MgSO4, 2.38 g/L HEPES, 0.39 g/L NaHCO3, 1 g/L glucose, 3.74 g/L 
Taurine, 1 g/L 2,3-Butanedione monoxime (all Sigma), and for 8 min with Collagenase II 
and Protease XIV (Worthington) and 0.03M CaCl2. Hearts were cut into small pieces and 
cells separated by gently pipetting for 3 minutes or until no large tissue pieces were 
observed. Cells were filtered through a 100 μm filter and washed in DMEM (Gibco). Cells 
were plated in DMEM with 20% FBS (GE Healthcare Life Sciences), nonessential amino 
acids (Sigma), Penicillin/Streptomycin, 2 mM L-Glutamine, and 25mM HEPES (all Quality 
Biological). Cells were incubated in a humidified 5% CO2 incubator at 37°C from here on. 
Non-adherent cells were washed away after 1 hour. Fibroblasts from second passage 
were used in experiments. The purity of cardiac fibroblast cultures was confirmed by 
qPCR and flow cytometry. Cells and supernatants were harvested at the indicated time 
points after addition of recombinant mouse cytokine IL-17A at 50 ng/mL or recombinant 
mouse GM-CSF at 50ng/mL (Peprotech). LEAFTM Purified anti-GM-CSF at 50µg/mL was 
used (MP1-22E9, BioLegend). Monocytes and fibroblasts separation in the co-culture 
was achieved by 0.4 µM transwell inserts (Corning). 
Parabiosis surgery 
Pairs of mice were anesthetized with inhaled isoflurane, 4.0–5.0% v/v induction (Baxter). 
Fur was removed thoroughly from the entire flank region using clippers. Anesthesia in 
surgical pairs was maintained with intramuscular injections of ketamine (80 mg/kg) and 
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xylazine (16 mg/kg). The mice were laid supine and the site was disinfected with 
betadine followed by 70% EtOH. We administered buprenorphine (0.1 mg/kg) 
intraperitoneally for initial analgesia, and at 12 hours postoperatively. Longitudinal 
incisions were made through the skin starting from the elbow joint and extended down 
to the knee joint. Non-absorbable 4-0 interrupted sutures were placed around the knee 
and elbow joints. Pairs where attached from the elbow joints first. To increase skin 
anastomosis, we used a continuous 5-0 absorbable vicryl sutures through the muscular 
layer and connect the pairs further, before attaching the knee joints. Surgical stapler 
was used to connect the skins of the pairs. Baytril was used upon completion of the 
procedure. Animals were provided with moistened chow and gel food diet supplement 
every other day until sacrifice at 19 to 20 days after parabiosis.  
EAM induction 
To induce EAM, we injected mice with 125 µg myosin heavy chain α peptide MyHCα614-
629 (Ac-SLKLMATLFSTYASAD; Genscript) [492] emulsified in CFA (Sigma-Aldrich) 
supplemented with 5mg/mL heat-killed Mycobacterium tuberculosis strain H37Ra (Difco) 
on days 0 and 7. On the first day of immunization, mice also received a dose of 500 ng 
pertussis toxins intraperitoneally (List Biologicals) [83].  
EAM histopathology assessments 
Myocarditis severity was evaluated by histology on days 21. Heart tissues were fixed in 
SafeFix solution (Thermo Fisher Scientific), embedded and cut into 5 µm serial sections. 
Sections were stained with H&E and ventricular inflammation was scored via a 
microscope by two independent blinded investigators and averaged using the following 
criteria for hematopoietic infiltrates: grade 0, no inflammation; grade 1, <10% of the heart 
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section is involved; grade 2, 10–30%; grade 3, 30–50%; grade 4, 50–90%; grade 5, >90% 
[83].   
Isolation of Splenic Ly6Chi and Ly6Clo monocytes 
Spleens from WT or IL-17Ra–/– BALB/c mice on day 14 of EAM were dissected and 
mechanically disrupted. Cells were filtered through 40 µm cell strainers and washed. 
Histopaque 1119 and 1077 (Sigma) were used to isolate mononuclear cells. Anti-Ly6G 
MicroBead kit (Miltenyi Biotech) was used to deplete Ly6G+ cells, and CD11b MicroBead 
kit (Miltenyi Biotech) was used to positively enrich CD11b+ cells. Single-cell suspensions 
were stained with LIVE/DEAD stain (ThermoFisher), washed, FcγRII/III blocked with a-
CD16/CD32, and stained with fluorochrome-conjugated antibodies (eBioscience, 
BioLegend, BD Pharmingen). Cells were sorted on an AriaIIu cell sorter. Sorted cells from 
IL-17Ra–/– BALB/c mice spleens were used for in vitro co-culture with primary cardiac 
fibroblasts, major outcomes were validated with sorted cells from WT BALB/c mice 
spleens co-cultured with cardiac fibroblasts. Sorted cells from WT BALB/c mice spleens 
were used in intracardiac transfer experiments (see below).  
Cell staining and light microscopy 
Modified Giemsa staining was achieved by using Differential Quik Stain Kit, following the 
manufacturer's instructions (Polysciences). Cell staining images were acquired on 
Olympus BX43 microscope with a camera (DP72) using CellSens Standard software 
(version 1.4.1; Olympus). 
IncuCyte ZOOM imaging  
Once the monocyte-fibroblast co-cultures were established, the plates were placed into 
the IncuCyte ZOOMTM (Essen Bioscience) apparatus and images of cells were recorded 
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with 20× magnification undisturbed every 1 hour for a total duration of 160 hours. Cardiac 
fibroblasts alone were used as controls and triplicated wells were included in all data 
acquisitions. 
Transmission electron microscopy 
Co-cultured cells were washed with PBS and fixed in 2.5% glutaraldehyde dissolved in 
0.1 M Na cacodylate. Samples were then processed by the Johns Hopkins Microscope 
Facility [493] before examination using the Philips CM120 transmission electron 
microscope. Images were captured using Advanced Microscopy Techniques V602 
software. The phagocytic index was calculated according to the following formula: 
phagocytic index = (total number of engulfed cells/total number of counted macrophages) 
× (number of macrophages containing engulfed cells/total number of counted 
macrophages) × 100. Approximately 60 total macrophages derived from each monocyte 
subset were counted, numbers were acquired from two separate assessments. 
Immunofluorescence microscopy 
Human paraffin-embedded giant cell myocarditis biopsy sample slides were processed 
using xylene and rehydrated with decreasing concentration of ethyl alcohol and rinsed 
with distilled water. After blocking with 1% BSA and 0.1% tween-20 in 1× PBS, tissues 
were incubated with anti-CD14-biotin sheep antibodies (R & D systems) and anti-CD68 
mouse antibodies (Abcam). We then used NL-637 Streptavidin and donkey NL-557 anti-
mouse IgG (R & D systems) as secondary antibodies diluted in 0.05% Evans Blue for 
counterstaining. DAPI was used for staining nuclei. Finally, Sudan Black was used to 
suppress auto-fluorescence as a result of tissue fixation and paraffin treatment. Images 
were acquired using Zeiss Axio Imager.A2. microscope with AxioCam MRm at 20× 
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magnification. We used AxioVision Rel. 4.8 software to acquire images and Adobe 
Photoshop version 12.0 to process images.   
Intracardiac injection 
WT or IL-17Ra–/– BALB/c mice on day 21 of EAM were depilated and anesthetized with 
3.5% isoflurane (Baxter). The mice were subsequently endotracheally intubated, 100% 
oxygen and 2% isoflurane were provided to the animals throughout the operation by 
mechanical ventilation (Model 845, Harvard Apparatus). Pre-operational analgesics (0.05 
mg/kg Buprenorphine, Reckitt Benckiser) and paralytics (1 mg/kg Succinylcholine, Henry 
Schein) were administered prior to operation. Mice were subjected to a thoracotomy, 
typically around the 4th or 5th intercostal space to expose the heart ventricles. Roughly 
1.5 – 2 x 105 cells were injected with a 29G ½ insulin syringe (BD) into 2 – 3 ventricular 
locations. Mice were placed under the heat lamp to recover post-surgery, post-operational 
analgesics (0.05 mg/kg Buprenorphine, Reckitt Benckiser) were administered. Mice were 
sacrifice at 40 hours and 160 hours post-surgery to assess cell transfer outcomes. 
Retro-orbital injection of monocytes 
WT or IL-17Ra–/– BALB/c mice on day 21 of EAM were depilated and anesthetized with 
100% oxygen and 3.5% isoflurane (Baxter). Mice were subjected to an injection into the 
ophthalmic venous sinus. Roughly 4 – 5 x 105 FACS sorted monocytes were injected with 
a 29G ½ insulin syringe (BD).  
Retro-orbital injection of liposomes and latex beads 
We administered a single treatment of 10 µl Clodrosome® (clodronate loaded liposomes; 
Encapsula Nano Sciences) per gram of animal weight seventeen hours prior to latex 
microsphere labeling to better visualize FITC+ macrophages in vivo. 0.5-µm FITC-
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conjugated (yellow gold) plain microspheres (2.5% solids [wt/vol]; Polysciences, Inc.) 
were diluted 1:25 in 1XPBS. We administered 250 µl of the diluted latex beads to examine 
macrophage phagocytic activity in vivo. Hearts were harvested 24 hours post bead 
administration. 
Quantitative reverse transcription PCR 
Cell mRNAs were extracted in TRIzol (Invitrogen), and reverse transcribed using High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Target cDNAs were 
amplified with Power SYBR Green PCR Master Mix (Bio-Rad) and real time cycle 
thresholds were detected via MyiQ2 themocycler running on an iQ5 software (Bio-Rad). 
Target genes fold induction were calculated using the 2−ΔΔCt method by normalizing cycle 
thresholds to the Hprt housekeeping gene and medium controls [494]. Verified Ccl2 
primer sequences were acquired from the PrimerBank (Harvard Medical School, 
Massachusetts General Hospital and The Center for Computational and Integrative 
Biology), and commercially synthesized (Integrated DNA Technologies). Ccl2 forward 
primer sequence (5’ to 3’): TTAAAAACCTGGATCGGAACCAA, and reverse primer 
sequence (5’ to 3’): GCATTAGCTTCAGATTTACGGGT. 
Flow cytometry analysis and Barnes-Hut Stochastic Neighbor Embedding analysis 
Hearts of naïve or EAM mice were perfused through the ventricles with PBS for 3 minutes. 
GentleMACS C Tubes were used to mechanically disassociate the tissue according to 
manufacturer's instructions (Miltenyi Biotech). Single cell suspensions were achieved 
using enzymatic digestion by 3000 U Collagenase II and 300 U DNase I (Worthington) 
dissolved in 5mL HBSS. Splenocytes, blood, and BM cells (femurs and tibias) were 
isolated by mechanical disruption, followed by red blood cell lysis using ACK buffer 
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(ThermoFisher). Heart samples were filtered through 40 µm filters, whereas the other 
tissues were filtered through 70 μm filters. Cells were then stained with LIVE/DEAD 
(ThermoFisher), FcγRII/III blocked with α-CD16/CD32, and stained with fluorochrome-
conjugated antibodies (eBioscience, BioLegend and BD Pharmingen). Alternatively, we 
used APC Annexin V Apoptosis Detection Kit with 7-AAD (BioLegend) instead of 
LIVE/DEAD. CellTraceTM CFSE Kit was used to track cell proliferation both in vivo and in 
vitro (ThermoFisher). Samples were acquired on a BD LSRII or LSRFortessa 4-laser 
cytometers running FACSDiva 6.0 (BD Immunocytometry) and analyzed using FlowJo 
10.4 software. We ran an interactive visualization tool called cyt in Matlab to analyze high-
dimensional flow cytometry data [445, 446]. bh-SNE is an unsupervised non-linear 
dimensionality reduction embedding technique [445].  
Microarray 
Ly6Chi and Ly6Clo in vitro co-culture derived macrophages in triplicate were FACS sorted 
and cells were lysed using RLT buffer (Qiagen). RNA was extracted using RNeasy micro 
kit. RNA samples were labeled using Thermal Fisher 3’ IVT Pico Reagent kit (Affymetrix) 
according to manufacturer’s guidelines and probed using the Affymetrix Mouse Clariom 
S Array. RNA concentration and integrity were determined with Agilent Bioanalyzer Pico 
Chip. 
Statistical analysis 
GraphPad Prism 7 software was used for statistical analysis. Statistical analysis details 
are described in the figure legends. To determine if datasets show a normal distribution, 
either the D'Agostino-Pearson or the Shapiro-Wilk normality test was used. P values were 
considered statistically significant at P<0.05. 
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Microarray gene expression analysis 
Raw data generated from Clariom S Arrays were processed using Affymetrix Expression 
Console Software. CEL files containing feature intensity values were converted into 
summarized expression values by Partek Genomic Suite Software including background 
adjustment, quantile normalization and summarization across all chips. All samples 
passed QC thresholds for hybridization, labeling and the expression of spiked in controls. 
The variances, both between and within groups, in log2 transformed expression values 
were analyzed by one-way ANOVA. PCA graph was generated using Partek Genomic 
Suite Software, heat maps were generated using TIBCO Spotfire Software. The complete 
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Conclusions and future directions 
 
In addition to myocardium, valves and an electrical conduction system, the heart depends 
on a complex network of cells, including cardiomyocytes, cardiac fibroblasts that produce 
extracellular matrix, endothelial cells and tissue macrophages, to provide the structure 
and function that allows the heart to pump oxygen and nutrients throughout the body [495]. 
As we begin to understand this complex network there has been an increasing interest in 
the roles played by the cardiac tissue macrophages in maintaining cardiac function [117, 
118, 147, 152, 153, 496]. Resident cardiac macrophages remove senescent and dying 
cells under steady-state and actively participate in the cardiac conduction system that 
maintains cardiac rhythm [497, 498]. Currently many attempts have been made to create 
immunotherapies that target macrophages. Unfortunately, global suppression or 
depletion of macrophage has been shown to have an adverse effect by contributing to 
heart failure [495]. Thus, it is imperative to dissect the functions of macrophage subsets 
to develop more specific treatments. Many new exciting technologies such as 
CRISPR/Cas9 gene editing, single cell sequencing, mass cytometry and intravital 
microscopy are available to transform our research and provide the opportunity to develop 
new therapies and biomarkers.  
My current work has demonstrated that, through direct contact, cardiac fibroblasts play a 
kely role in the monocyte-to-macrophage differentiation of both Ly6Chi and Ly6Clo cells 
recruited to the heart. Ly6Chi monocyte-derived macrophages differentiate to primaryilgy 
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phagocytic cells, whereas Ly6Clo monocyte-derived macrophages transform to cells that 
predominantly express MHCII and show the potential for antigen presentation. 
Furthermore, a cardiac milieu rich in IL-17A can induce GM-CSF production from cardiac 
fibroblasts which inhibits Ly6Clo monocyte-to-macrophages differentiation downstream. 
IL-17A signaling through cardiac fibroblasts also enhances MerTK proteolytic cleavage, 
which dampens phagocytic capabilities of Ly6Chi monocyte-derived macrophages. IL-17A 
is the most dominant cytokine produced in the myocardium of both mice and humans with 
myocarditis. It has been shown previously that IL-17A is essential for EAM progression 
into DCM [442]. Therefore, we hypothesize that reduced macrophage phagocytic activity 
as a result of IL-17A signaling contributes to myocarditis pathogenesis. We found that 
MHCII is highly and most predominantly expressed by Ly6Clo monocyte-derived 
macrophages, coinciding with higher MHCII expression in the macrophage compartment 
in IL-17Ra–/– EAM mice when compared to WT controls. However, we were unable to 
elucidate the exact role of Ly6Clo monocyte-derived macrophages during myocarditis at 
this time.  
Several questions remain unanswered. Are these Ly6Clo monocyte-derived macrophages 
presenting antigens to T effector cells or to T regulatory cells? Do Ly6Clo monocyte-
derived macrophages travel to the draining lymph nodes or remain static in the 
myocardium during antigen presentation? Do Ly6Clo monocyte-derived macrophages 
contribute to steady state cardiac macrophage pool? We plan to use latex bead labeling 
to track blood Ly6Clo monocytes establishment in the myocardium during EAM [177, 299, 
499]. However, several caveats exist for this technique. First, labeling kinetics declines 
steadily over time and less than 5% of the blood Ly6Clo monocytes are still labeled by day 
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7 [499]. EAM is a chronic disease that requires 7 days to induce and 14 more days to fully 
develop (Figure 1). Therefore, Ly6Clo monocytes should ideally be labeled between the 
initiation and the peak of cardiac infiltration (day 12 to day 21) to fully capture the change 
of Ly6Clo monocytes during EAM. Unfortunately, it has been shown that latex beads label 
similar percentages of Ly6Chi and Ly6Clo monocytes in vivo during the first few hours 
[499]. This means that labeled Ly6Chi monocytes can established themselves as 
macrophages in the myocardium, which could severely confound the result and its 
interpretation. Alternatively, we can utilize IL-17Ra–/–Nr4a1–/– EAM mice to determine if 
these IL-17Ra deficient mice will continue to develop DCM when Ly6Clo monocytes are 
absent.  
Previously we uncovered a protective role for IL-13 in EAM development. IL-13–/– EAM 
mice were shown to have a decreased number of anti-inflammatory macrophages present 
in the myocardium [500]. Recently I have shown that the IL-13 receptor IL-13Ra1 is highly 
expressed by macrophages in the naïve heart (Figure 19A). Heart ILCs are the most 
predominant IL-13 producers in naïve hearts (Figure 19B). The percentage of ILCs wanes 
as EAM progresses, which surprisingly coincides with IL-13Ra1 down-regulation on 
macrophages as well (data not shown). We are currently investigating whether 
macrophage phenotypes are altered in ILC deficient Rag2–/–𝛾c–/– mice. 
In summary, our findings demonstrate that monocyte and macrophage fates and 
functions are fine-tuned by both intrinsic and environmental factors. Macrophages 
constitute a double-edged sword in cardiac injury and inflammation. It is still largely 
unknown whether macrophage heterogeneity and remarkable versatility is a 
consequence of changes at a single cell level (genetic and epigenetic alteration) or at a 
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population level (proliferation, cell death, recruitment or egress). Technologies are 
currently still limited that would allow us to readily and precisely distinguish tissue-resident 
macrophages from monocyte-derived macrophages upon establishment of tissue 





Figure 19. IL-13Ra1 expressing cells and IL-13 producing cells during EAM development 
(A) Percentages of IL-13Ra1 expressing cells out of total live cells in naïve mice 
myocardium. (B) Percentages of IL-13 producing cells out of overall lymphocytic 
population during EAM development. 
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The ongoing debates about the role of cardiac fibroblasts 
Since cardiac fibroblasts play a role in facilitating monocyte-to-macrophage differentiation, 
we will discuss here what is currently known about cardiac fibroblasts.  
It is estimated that about 10% of the total cells in adult mouse myocardium are fibroblasts 
[249]. We are beginning to understand the ontogeny and fundamental role of cardiac 
tissue-resident fibroblasts in disease and health. There are two opposing theories 
describing the origin of resident fibroblasts. One states that cardiac fibroblasts originate 
from a variety of cell types (including endothelial cells [501, 502], pericytes and leukocytes 
[503-505]) that requires further trans-differentiation to become activated. The other states 
that adult cardiac resident fibroblasts originate from the epicardium during embryogenesis 
and contribute to activated fibroblasts or myofibroblasts during injury [506]. A recent 
genetic lineage tracing study that supports the latter theory showed that cardiac resident 
fibroblasts are the primary source of activated fibroblasts after MI and pressure overload 
[507].  
It is now clear that cardiac fibroblasts are potent producers of pro-inflammatory cytokines, 
chemokines and extracellular matrix during cardiac inflammation and heart failure [247, 
508]. Specifically, GM-CSF production by fibroblasts has been implicated in the 
pathogenesis of EAM, MI and Kawasaki disease [247, 460, 509]. Cardiac fibroblasts are 
highly plastic and heterogenous. We have recently demonstrated that cardiac 
inflammation triggers the expansion of CD45–CD31–CD29+mEFSK4+PDGFα+Sca-
1+periostin+ fibroblast population in mice, which is a major producer of GM-CSF as well 
as CCL2 [508]. Fibroblasts co-expressing GM-CSF and CCL2 could also be found in 
human myocardial biopsy samples in both myocarditis and ischemic heart failure patients 
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[508]. Ablation of GM-CSF production in fibroblasts or fibroblast subsets that produce 
GM-CSF protects mice from heart failure [508, 510]. We therefore speculate that 
fibroblast-specific ablation of GM-CSF production permits Ly6Clo monocytes to become 
reparative macrophages in the heart to promote adequate cardiac remodeling and 
inflammation resolution. 
Before we propose that cardiac fibroblasts can be used as potential therapeutic targets, 
it is important to address whether macrophages can also influence cardiac fibroblast 
activation status. Interaction between macrophages and fibroblasts via both soluble 
factors and direct cell-cell contact is most likely not a one-way street. Therefore, a better 
understanding of the roles and functions of cardiac fibroblasts will be useful to target 
maladaptive fibrosis in human cardiovascular diseases. 
Pericardial and peritoneal macrophages – two facets of a kind? 
The heart is enclosed in the pericardium, a cavity filled with protective serosal fluid. 
Macrophages are found residing in human serosal fluid [511]. Recently, Kubes and 
colleagues demonstrated that F4/80+GATA-6+ murine peritoneal macrophages are 
rapidly mobilized to promote tissue repair after acute sterile liver injury [512]. Thus, the 
concept that peritoneum serves as a reparative macrophage reservoir during acute injury 
can be potentially extended to other serosal populations, including pericardial cavities. It 
is unclear whether pericardial macrophages can actively infiltrate the myocardium during 
cardiac injury. Also, it will be interesting to know their specific function during heart 
inflammation.  
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We obtained pericardial effusion samples from 5 patients with chronic ischemic heart 
diseases who underwent coronary artery bypass grafting. Control blood samples were 
collected from a healthy donor, whose peripheral blood mononuclear cells (PBMCs) were 
isolated for comparison purposes. All patients in the study provided informed consent. 
Our preliminary data suggested that while CD14+CD16- monocytes accounted for the 
most predominant population in blood [183, 513], pericardial effusion samples consisted 
almost entirely of CD14+CD16+CD68+CD64+ macrophage population (Figure 20). 
Additionally, the monocyte/macrophage population in pericardial effusion express high 
levels of CD206, HLA-DR and CD116 when compared to blood monocytes (Figure 20). 
Next, we compared peritoneal, pericardial and myocardial F4/80hiCD64+ macrophages in 
naïve mice. We found that peritoneal and pericardial macrophages express high levels of 




Figure 21). These GATA-6+ macrophages can infiltrate the myocardium post MI (data not 
shown). 
Although the origin of pericardial macrophages is unknown, similarity between peritoneal 
and pericardial macrophages suggests that pericardial macrophages may also carry 
reparative features. Together with embryonic macrophages and Ly6Clo monocyte-derived 
macrophages, they could play protective roles during cardiac injury. Our initial findings 
warrant rigorous future studies to elucidate the ontogeny and function of these pericardial 
macrophages, as well as their identities distinct from myocardial macrophages, which 
may shed light on their roles in health and disease.  
Our knowledge of tissue macrophages has evolved significantly over the past decade. 
We have gained an appreciation that macrophage activation is multifaceted in the context 
of tissue injury. Future therapeutic manipulation to improve disease outcomes require 
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careful examination of macrophage subsets and functions. Our work studying the role of 
macrophages in myocarditis will advance our understanding of pathogenesis, diagnosis 
and treatment of chronic heart failure.    
Figure 20. Pericardial macrophage phenotype 
(A) Top panel shows flow cytometry gating of CD14 and CD16 from a healthy donor’s 
total live CD45+Lin– (lineage including CD3e, CD19, CD56 and CD66b) peripheral blood 
mononuclear cells (PBMCs). Lower panel shows CD64+CD68+ macrophages out of total 
live CD45+Lin–CD62L– PBMC. (B) Top panel shows representative gating of CD14 and 
CD16 cells from total live CD45+Lin– cells present in the pericardial effusion fluid of 
patients with chronic ischemic heart diseases. Lower panel shows these patient’s 
CD64+CD68+ macrophages out of total live CD45+Lin–CD62L– cells in the pericardial 
effusion.  (C) Histograms of MFI showing different markers’ expression of cells in healthy 





Figure 21. Pericardial macrophages are similar to peritoneal macrophages in CD44 and 
GATA-6 co-expression 
(A) Histograms of CD44 MFI and (B) GATA-6 MFI showing murine (red) peritoneal 
macrophages, (purple) pericardial macrophages, and (grey) myocardial macrophages. 






Our work in the past has demonstrated that the recruitment of Ly6Chi monocytes in large 
numbers to the myocardium contributes to a greater Ly6Chi to Ly6Clo 
monocyte/macrophage ratio in the heart which promotes EAM to DCM development 
(Figure 22A). Current results highlight that Ly6Chi monocytes contribute to a macrophage 
population that is highly pro-inflammatory, pro-tissue remodeling and is deficient in 
phagocytic activities in an IL-17A rich cardiac environment. This supports our main 
hypothesis on which our work is based. However, we also found that IL-17A plays a 
suppressive role through signaling to cardiac fibroblasts by inhibiting Ly6Clo monocytes 
to become MHCII+ macrophages (Figure 22B). While the role of Ly6Clo monocyte-derived 
MHCII+ macrophages warrants future in-depth examination, we hypothesize that they are 
associated with DCM protection in IL-17A deficient animals. In summary, our finding has 








Figure 22. Past and current models explaining the disease pathogenesis of EAM and 
DCM  
(A) Past model suggesting that the Ly6Chi to Ly6Clo ratio is associated with EAM to DCM 
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